<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Arch Dermatol Res</journal-id>
      <journal-title>Archives of Dermatological Research</journal-title>
      <issn pub-type="ppub">0340-3696</issn>
      <issn pub-type="epub">1432-069X</issn>
      <publisher>
        <publisher-name>Springer-Verlag</publisher-name>
        <publisher-loc>Berlin/Heidelberg</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">17221215</article-id>
      <article-id pub-id-type="pmc">1800369</article-id>
      <article-id pub-id-type="publisher-id">726</article-id>
      <article-id pub-id-type="doi">10.1007/s00403-006-0726-5</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Review Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Serologic and immunohistochemical prognostic biomarkers of cutaneous malignancies</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Utikal</surname>
            <given-names>Jochen</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Schadendorf</surname>
            <given-names>Dirk</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name name-style="western">
            <surname>Ugurel</surname>
            <given-names>Selma</given-names>
          </name>
          <address>
            <phone>+49-621-3833905</phone>
            <fax>+49-621-3832163</fax>
            <email>s.ugurel@dkfz.de</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <aff id="Aff1"><label>1</label>Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl-University of Heidelberg,  Theodor-Kutzer-Ufer 1-3, 68135 Mannheim, Germany </aff>
        <aff id="Aff2"><label>2</label>Skin Cancer Unit, German Cancer Research Center, Heidelberg, Germany </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>13</day>
        <month>1</month>
        <year>2007</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>3</month>
        <year>2007</year>
      </pub-date>
      <volume>298</volume>
      <issue>10</issue>
      <fpage>469</fpage>
      <lpage>477</lpage>
      <history>
        <date date-type="received">
          <day>3</day>
          <month>11</month>
          <year>2006</year>
        </date>
        <date date-type="rev-recd">
          <day>6</day>
          <month>12</month>
          <year>2006</year>
        </date>
        <date date-type="accepted">
          <day>6</day>
          <month>12</month>
          <year>2006</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Springer-Verlag 2006</copyright-statement>
      </permissions>
      <abstract>
        <p>Biomarkers are important tools in clinical diagnosis and prognostic classification of various cutaneous malignancies. Besides clinical and histopathological aspects (e.g. anatomic site and type of the primary tumour, tumour size and invasion depth, ulceration, vascular invasion), an increasing variety of molecular markers have been identified, providing the possibility of a more detailed diagnostic and prognostic subgrouping of tumour entities, up to even changing existing classification systems. Recently published gene expression or proteomic profiling data relate to new marker molecules involved in skin cancer pathogenesis, which may, after validation by suitable studies, represent future prognostic or predictive biomarkers in cutaneous malignancies. We, here, give an overview on currently known serologic and newer immunohistochemical biomarker molecules in the most common cutaneous malignancies, malignant melanoma, squamous cell carcinoma and cutaneous lymphoma, particularly emphasizing their prognostic and predictive significance.</p>
      </abstract>
      <kwd-group>
        <title>Keywords</title>
        <kwd>Skin cancer</kwd>
        <kwd>Biomarker</kwd>
        <kwd>Prognosis</kwd>
        <kwd>Serum</kwd>
        <kwd>Immunohistochemistry</kwd>
      </kwd-group>
      <custom-meta-wrap>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; Springer-Verlag 2007</meta-value>
        </custom-meta>
      </custom-meta-wrap>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1" sec-type="introduction">
      <title>Introduction</title>
      <p>Biomarkers play an important role in the diagnosis and prognostic classification of various cancer entities and can moreover be useful in monitoring the patient&#x2019;s clinical course of disease and response to therapy. In general, biomarkers are proteins, less often carbohydrates or lipids, and their expression profiles are associated with malignant disease. In the majority of cases, the marker molecules are expressed by the tumour cells themselves or by cells of the tumour microenvironment. Thus, most biomarkers can primarily be found in malignant tissues, but after active secretion or passive release at tumour cell destruction also become detectable in body fluids like blood, lymph or urine.</p>
      <p>Besides morphological and histopathological biomarkers (anatomic site and type of the primary tumour, tumour size and invasion depth, ulceration, vascular invasion), an increasing variety of molecular markers have been identified, providing the possibility of a more detailed diagnostic and prognostic subgrouping of tumour entities, up to even changing existing classification systems. Recently published gene expression, as well as proteomic profiling data, indicates new candidate molecules involved in skin cancer pathogenesis, which may after further validation represent new markers superior to existing ones. This ongoing process of biomarker identification and validation would result in a rapidly changing molecular view and classification of skin cancers.</p>
    </sec>
    <sec id="Sec2">
      <title>Malignant melanoma</title>
      <sec id="Sec3">
        <title>Serologic markers of malignant melanoma</title>
        <p>Despite numerous therapeutic options, the prognosis of malignant melanoma, once metastasized, is still poor. Thus, the search for reliable methods to detect metastases as early as possible and to identify patients with high risk of disease progression is of major importance. The serological parameters most widely used for the early detection of a tumour relapse or metastasis in the follow-up of melanoma patients are the melanocyte lineage/differentiation antigens S100-beta and melanoma inhibitory activity (MIA) (see Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref> and Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>). Both proteins are with high, but not exclusive, specificity expressed by melanoma cells and thus correlate with the patient&#x2019;s tumour load.
<table-wrap id="Tab1"><label>Table&#xA0;1</label><caption><p>Serologic markers of malignant melanoma</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Serologic marker</th><th align="left">Selected literature</th></tr></thead><tbody><tr><td align="left" rowspan="5">Melanocyte lineage/differentiation antigens</td><td align="left">S100-beta</td><td align="left">[<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR71">71</xref>, <xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]</td></tr><tr><td align="left">MIA (melanoma inhibitory activity)</td><td align="left">[<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR74">74</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]</td></tr><tr><td align="left">Tyrosinase</td><td align="left">[<xref ref-type="bibr" rid="CR2">2</xref>]</td></tr><tr><td align="left">5-S-Cysteinyldopa</td><td align="left">[<xref ref-type="bibr" rid="CR91">91</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]</td></tr><tr><td align="left">L-Dopa/L-tyrosine</td><td align="left">[<xref ref-type="bibr" rid="CR75">75</xref>]</td></tr><tr><td align="left" rowspan="3">Proangiogenic factors</td><td align="left">VEGF (vascular endothelial growth factor)</td><td align="left">[<xref ref-type="bibr" rid="CR83">83</xref>, <xref ref-type="bibr" rid="CR56">56</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]</td></tr><tr><td align="left">BFGF (basic fibroblast growth factor)</td><td align="left">[<xref ref-type="bibr" rid="CR83">83</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]</td></tr><tr><td align="left">IL-8 (Interleukin-8)</td><td align="left">[<xref ref-type="bibr" rid="CR68">68</xref>, <xref ref-type="bibr" rid="CR83">83</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]</td></tr><tr><td align="left" rowspan="3">Molecules involved in cell adhesion and motility</td><td align="left">sICAM-1 (soluble intracellular adhesion molecule 1)</td><td align="left">[<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR87">87</xref>, <xref ref-type="bibr" rid="CR94">94</xref>]</td></tr><tr><td align="left">sVCAM (soluble vascular cell adhesion molecule 1)</td><td align="left">[<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR87">87</xref>]</td></tr><tr><td align="left">Matrix metalloproteinases (MMP)-1 and 9</td><td align="left">[<xref ref-type="bibr" rid="CR63">63</xref>, <xref ref-type="bibr" rid="CR53">53</xref>]</td></tr><tr><td align="left" rowspan="3">Cytokines and cytokine receptors</td><td align="left">IL-6 (Interleukin-6)</td><td align="left">[<xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR73">73</xref>]</td></tr><tr><td align="left">IL-10 (Interleukin-10)</td><td align="left">[<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR51">51</xref>]</td></tr><tr><td align="left">sIL-2R (soluble interleukin-2-receptor)</td><td align="left">[<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR58">58</xref>]</td></tr><tr><td align="left" rowspan="2">HLA molecules</td><td align="left">sHLA-DR (soluble HLA-DR)</td><td align="left">[<xref ref-type="bibr" rid="CR62">62</xref>]</td></tr><tr><td align="left">sHLA-class-I (soluble HLA-class I)</td><td align="left">[<xref ref-type="bibr" rid="CR89">89</xref>]</td></tr><tr><td align="left" rowspan="8">Others</td><td align="left">LDH (lactate dehydrogenase)</td><td align="left">[<xref ref-type="bibr" rid="CR72">72</xref>, <xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]</td></tr><tr><td align="left">CRP (C-reactive protein) </td><td align="left">[<xref ref-type="bibr" rid="CR19">19</xref>]</td></tr><tr><td align="left">Albumin</td><td align="left">[<xref ref-type="bibr" rid="CR72">72</xref>]</td></tr><tr><td align="left">TuM2-PK (Tumour pyruvate kinase type M2)</td><td align="left">[<xref ref-type="bibr" rid="CR81">81</xref>]</td></tr><tr><td align="left">sFas/CD95 </td><td align="left">[<xref ref-type="bibr" rid="CR84">84</xref>]</td></tr><tr><td align="left">YKL-40</td><td align="left">[<xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR70">70</xref>]</td></tr><tr><td align="left">CYT-MAA (cytoplasmic melanoma-associated antigen)</td><td align="left">[<xref ref-type="bibr" rid="CR85">85</xref>]</td></tr><tr><td align="left">HMW-MAA (high-molecular-weight melanoma-associated antigen)</td><td align="left">[<xref ref-type="bibr" rid="CR85">85</xref>]</td></tr></tbody></table></table-wrap><fig id="Fig1"><label>Fig.&#xA0;1</label><caption><p>Schematic presentation of the cellular localization and function of the melanoma biomarkers S100-beta, tyrosinase and melanoma inhibitory activity (<italic>MIA</italic>)</p></caption><graphic position="anchor" xlink:href="403_2006_726_Fig1_HTML" id="MO1"/></fig></p>
        <p>The S100 protein is a 21-kDa thermo-labile acidic dimeric protein, which was originally isolated from the central nervous system (CNS) [<xref ref-type="bibr" rid="CR49">49</xref>]. It consists of two subunits, alpha and beta, in the combinations alpha/alpha, alpha/beta and beta/beta. S100 affects the assembly and disassembly of microtubules and also interacts in a calcium-dependent manner with the p53 tumour suppressor gene. The beta subunit is expressed in cells of the central nervous system as well as in cells of the melanocytic lineage. Therefore, S100-beta measured in the cerebrospinal fluid was known as a marker of CNS damage [<xref ref-type="bibr" rid="CR59">59</xref>], years before S100-beta was shown to be a useful serum marker in melanoma [<xref ref-type="bibr" rid="CR30">30</xref>]. MIA was originally detected in melanoma cell culture supernatant [<xref ref-type="bibr" rid="CR9">9</xref>] and was shown to exert an important role in cell&#x2013;matrix interaction and metastasis [<xref ref-type="bibr" rid="CR8">8</xref>].</p>
        <p>Serum S100-beta has been shown to be superior compared to MIA, as an early indicator of tumour progression, relapse or metastasis [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR43">43</xref>], and its distribution as a serum biomarker of melanoma, therefore, is the broadest [<xref ref-type="bibr" rid="CR36">36</xref>]. Both markers have been shown to be useful prognostic markers in melanoma patients with distant metastases (stage IV, classification system of the American Joint Committee on Cancer, AJCC, see Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>) [<xref ref-type="bibr" rid="CR71">71</xref>, <xref ref-type="bibr" rid="CR33">33</xref>], but fail to provide prognostic significance in early stages of melanoma, especially in patients who are tumour-free after surgical procedures [<xref ref-type="bibr" rid="CR74">74</xref>]. Because of the strong correlation of their serum concentrations with the patients&#x2019; tumour load, S100-beta and MIA are useful markers in the monitoring of therapy response in advanced metastatic melanoma patients (AJCC stage IV) [<xref ref-type="bibr" rid="CR32">32</xref>]. Again, none of both markers are suitable indicators of therapy response in tumour-free early-stage melanoma patients (AJCC stage II or III). Moreover, S100-beta has been shown to fail to identify patients with lymph node micrometastases detected by sentinel node procedure [<xref ref-type="bibr" rid="CR1">1</xref>].
<fig id="Fig2"><label>Fig.&#xA0;2</label><caption><p>Kaplan&#x2013;Meier survival curves of 65 patients with advanced metastatic melanoma (AJCC stage IV). Patients with elevated serum levels of S100-beta show a significantly reduced survival probability compared to patients with normal S100-beta serum concentrations (<italic>P</italic>&#xA0;=&#xA0;0.003 by log rank test; detection system LIAISON Sangtec 100)</p></caption><graphic position="anchor" xlink:href="403_2006_726_Fig2_HTML" id="MO2"/></fig></p>
        <p>The strongest prognostic serum biomarker in advanced metastatic melanoma is lactate dehydrogenase (LDH), an unspecific marker indicating high tumour load in a variety of tumour entities, including melanoma. Studies comparing LDH, S100-beta and MIA using multivariate data analysis showed LDH to be the strongest independent prognostic factor in stage IV melanoma patients [<xref ref-type="bibr" rid="CR18">18</xref>]. Due to its high prognostic significance, coupled with its easy, cost-efficient and widely distributed detection methodology, serum LDH is the only molecular marker that has been included in the current melanoma staging and classification system of the AJCC [<xref ref-type="bibr" rid="CR6">6</xref>]. It, moreover, serves as a stratification parameter in most randomized therapy trials performed in stage-IV melanoma and may also be used to monitor therapy response in these patients.</p>
        <p>A variety of other molecules of peripheral blood have been described as markers of tumour load and disease progression in melanoma. These biomarkers are derived from different fields like melanocytic differentiation (e.g. tyrosinase; see Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>), tumour angiogenesis (e.g. VEGF, bFGF, IL-8), cell adhesion and motility (e.g. ICAM-1, MMPs), cytokines and their receptors (e.g. IL-6, IL-10), antigen presentation (e.g. HLA molecules), tumour cell metabolism (e.g. TuM2-PK), apoptosis (e.g. Fas/CD95) and many others (see Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>). However, neither one of these markers could be confirmed to be superior to S100-beta or LDH in reflecting the prognosis of patients in advanced disease stages, nor could any marker be shown to be of strong prognostic relevance in early stage tumour-free patients.</p>
        <p>The serum proteomic profiling is an innovative approach to identify new, potentially better serological biomarkers in melanoma. This methodology offers the possibility of screening the whole serum proteome for markers, which match different criteria like prognostic significance, prediction of therapy response, etc. Using this technology, marker proteins from thematic fields, different from the above-mentioned ones, might be found and thereafter validated for their clinical use. The first promising results have been obtained and are currently tested in large sets of serum samples [<xref ref-type="bibr" rid="CR46">46</xref>].</p>
      </sec>
      <sec id="Sec4">
        <title>Immunohistochemical markers of malignant melanoma</title>
        <p>Cutaneous malignant melanoma regularly develops from the radial to the vertical growth phase and thereafter to metastatic disease. The variability of this clinical course is only partially explained by morphological and histopathological parameters like primary tumour localization, patient gender and age, mitotic rate, tumour thickness and ulceration. There is a need to identify molecular variables, which help to assign patients to specific risk groups. The number of modalities for diagnosing and subclassifying malignant melanomas is rapidly increasing and includes immunohistochemistry of tissue sections and microarrays, gene expression profiling, comparative genomic hybridization and mutational analysis. These methodologies promise to improve our prognostic classification systems, as well as our diagnostic and therapeutic potential.</p>
        <p>For diagnostic purposes, a small panel of melanocytic lineage markers, e.g. S100, MART-1/MelanA and gp100/HMB45, is sufficient to distinguish melanoma from non-melanocytic cancers. For the differentiation between benign and malignant melanocytic lesions, a review of immunohistochemical markers is given in ref. [<xref ref-type="bibr" rid="CR44">44</xref>]. The present review focuses on newer markers with potential prognostic impact for the disease. For this purpose, the situation is more complex. The transformation from benign melanocytes to metastatic melanoma is the result of a compilation of genetic alterations crucial to cell division, differentiation, anti-apoptosis, invasion, angiogenesis and sustenance in a microenvironment distant from the point of origin of the cell. Several marker molecules involved in these genetic alterations have been identified, and their expression in primary melanoma has been studied and correlated with the prognosis. Table&#xA0;<xref rid="Tab2" ref-type="table">2</xref> gives a current overview on already identified biomarkers, whose abnormal expression is associated with the patient&#x2019;s prognosis. It may be expected that the most detailed prognostic classification will result not from one, but rather from a panel of multiple biomarkers from this list.
<table-wrap id="Tab2"><label>Table&#xA0;2</label><caption><p>Immunohistochemical markers of malignant melanoma associated with prognosis</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Association with poor prognosis</th><th align="left">Selected literature</th></tr></thead><tbody><tr><td align="left" colspan="3">Melanocyte lineage/Differentiation antigens</td></tr><tr><td align="left">&#xA0;gp100/HMB45</td><td align="left">Increased expression</td><td align="left">[<xref ref-type="bibr" rid="CR52">52</xref>]</td></tr><tr><td align="left" colspan="3">Tumour suppressors/oncogenes/signal transducers</td></tr><tr><td align="left">&#xA0;p16 <sup>INK4A</sup></td><td align="left">Decreased expression</td><td align="left">[<xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]</td></tr><tr><td align="left">&#xA0;PTEN</td><td align="left">Decreased expression</td><td align="left">[<xref ref-type="bibr" rid="CR48">48</xref>]</td></tr><tr><td align="left">&#xA0;pRb (retinoblastoma protein)</td><td align="left">Inactivation due to protein phosphorylation</td><td align="left">[<xref ref-type="bibr" rid="CR65">65</xref>]</td></tr><tr><td align="left">&#xA0;EGFR (epidermal growth factor receptor)</td><td align="left">Increased expression</td><td align="left">[<xref ref-type="bibr" rid="CR80">80</xref>]</td></tr><tr><td align="left">&#xA0;p-Akt (activated serine-threonine protein kinase B)</td><td align="left">Increased expression</td><td align="left">[<xref ref-type="bibr" rid="CR17">17</xref>]</td></tr><tr><td align="left">&#xA0;c-Kit</td><td align="left">Expression</td><td align="left">[<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR82">82</xref>]</td></tr><tr><td align="left">&#xA0;c-myc</td><td align="left">Increased expression</td><td align="left">[<xref ref-type="bibr" rid="CR42">42</xref>]</td></tr><tr><td align="left">&#xA0;AP-2 (activator protein-2alpha) transcription factor</td><td align="left">Loss of nuclear AP-2 expression</td><td align="left">[<xref ref-type="bibr" rid="CR7">7</xref>]</td></tr><tr><td align="left">&#xA0;HDM2 (human homologue of murine mdm2)</td><td align="left">Increased expression</td><td align="left">[<xref ref-type="bibr" rid="CR61">61</xref>]</td></tr><tr><td align="left">bcl-6</td><td align="left">Expression</td><td align="left">[<xref ref-type="bibr" rid="CR3">3</xref>]</td></tr><tr><td align="left" colspan="3">Cell cycle associated proteins</td></tr><tr><td align="left">&#xA0;Ki67 (detected by Mib1)</td><td align="left">Increased expression</td><td align="left">[<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR57">57</xref>]</td></tr><tr><td align="left">&#xA0;Cyclin A, B, D, E</td><td align="left">Increased expression</td><td align="left">[<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]</td></tr><tr><td align="left">&#xA0;p21<sup>CIP1</sup></td><td align="left">Decreased expression</td><td align="left">[<xref ref-type="bibr" rid="CR3">3</xref>]</td></tr><tr><td align="left">&#xA0;Geminin</td><td align="left">Increased expression</td><td align="left">[<xref ref-type="bibr" rid="CR92">92</xref>]</td></tr><tr><td align="left">&#xA0;PCNA (proliferating cell nuclear antigen)</td><td align="left">Increased expression</td><td align="left">[<xref ref-type="bibr" rid="CR92">92</xref>]</td></tr><tr><td align="left" colspan="3">Regulators of apoptosis</td></tr><tr><td align="left">&#xA0;bcl-2</td><td align="left">Increased expression</td><td align="left">[<xref ref-type="bibr" rid="CR78">78</xref>]</td></tr><tr><td align="left">&#xA0;bax </td><td align="left">Decreased expression</td><td align="left">[<xref ref-type="bibr" rid="CR23">23</xref>]</td></tr><tr><td align="left">&#xA0;Bak</td><td align="left">Decreased expression</td><td align="left">[<xref ref-type="bibr" rid="CR23">23</xref>]</td></tr><tr><td align="left">&#xA0;APAF-1 (Apoptotic protease activating factor-1)</td><td align="left">Decreased expression</td><td align="left">[<xref ref-type="bibr" rid="CR27">27</xref>]</td></tr><tr><td align="left">&#xA0;Surviving</td><td align="left">Increased expression</td><td align="left">[<xref ref-type="bibr" rid="CR78">78</xref>]</td></tr><tr><td align="left" colspan="3">Molecules involved in angiogenesis</td></tr><tr><td align="left">&#xA0;LYVE-1 (lymphatic vascular endothelial hyaluronan receptor-1) </td><td align="left">Increased expression</td><td align="left">[<xref ref-type="bibr" rid="CR16">16</xref>]</td></tr><tr><td align="left">&#xA0;PTN (pleiotrophin)</td><td align="left">Increased expression</td><td align="left">[<xref ref-type="bibr" rid="CR93">93</xref>]</td></tr><tr><td align="left" colspan="3">Molecules involved in cell adhesion and motility</td></tr><tr><td align="left">&#xA0;P-Cadherin</td><td align="left">Strong cytoplasmic expression</td><td align="left">[<xref ref-type="bibr" rid="CR5">5</xref>]</td></tr><tr><td align="left">&#xA0;E-Cadherin</td><td align="left">Decreased expression</td><td align="left">[<xref ref-type="bibr" rid="CR4">4</xref>]</td></tr><tr><td align="left">&#xA0;Beta-catenin</td><td align="left">Loss of nuclear staining</td><td align="left">[<xref ref-type="bibr" rid="CR5">5</xref>]</td></tr><tr><td align="left">&#xA0;Integrins beta1 and beta3 </td><td align="left">Increased expression</td><td align="left">[<xref ref-type="bibr" rid="CR66">66</xref>]</td></tr><tr><td align="left">&#xA0;MMPs (matrix metalloproteinases)</td><td align="left">Increased expression</td><td align="left">[<xref ref-type="bibr" rid="CR63">63</xref>]</td></tr><tr><td align="left">&#xA0;Dysadherin</td><td align="left">Increased expression</td><td align="left">[<xref ref-type="bibr" rid="CR54">54</xref>]</td></tr><tr><td align="left">&#xA0;CEACAM1 (carcinoembryonic-antigen-related cell-adhesion molecule 1)</td><td align="left">Increased expression</td><td align="left">[<xref ref-type="bibr" rid="CR79">79</xref>]</td></tr><tr><td align="left">&#xA0;Osteonectin (also termed BM40 or SPARC (secreted protein, acidic and rich in cysteine))</td><td align="left">Increased expression</td><td align="left">[<xref ref-type="bibr" rid="CR45">45</xref>]</td></tr><tr><td align="left" colspan="3">Others </td></tr><tr><td align="left">&#xA0;TA (telomerase activity) </td><td align="left">Increased expression</td><td align="left">[<xref ref-type="bibr" rid="CR13">13</xref>]</td></tr><tr><td align="left">&#xA0;Melastatin</td><td align="left">Decreased expression</td><td align="left">[<xref ref-type="bibr" rid="CR22">22</xref>]</td></tr><tr><td align="left">&#xA0;ALCAM/CD166 (Activated leukocyte cell adhesion molecule)</td><td align="left">Increased expression</td><td align="left">[<xref ref-type="bibr" rid="CR77">77</xref>]</td></tr><tr><td align="left">&#xA0;CXCR4 receptor</td><td align="left">Increased expression</td><td align="left">[<xref ref-type="bibr" rid="CR67">67</xref>]</td></tr><tr><td align="left">&#xA0;Metallothionein</td><td align="left">Increased expression</td><td align="left">[<xref ref-type="bibr" rid="CR88">88</xref>]</td></tr></tbody></table></table-wrap></p>
        <p>In a recent retrospective study, frozen tissue samples from primary melanomas with long-term clinical follow-up were analysed using a pangenomic oligonucleotide microarray [<xref ref-type="bibr" rid="CR92">92</xref>]. The authors describe a signature of 174 genes, identifying patients at risk to develop distant metastasis. From these 174 genes, 141 were under-expressed and 33 were over-expressed in primary melanomas of patients who remained free of metastasis for 4&#xA0;years. About 30 of these 174 genes have already been studied in melanoma and include genes involved in cell cycle (CKS2, CDC2, CCNB1, CENPF and DHFR), mitosis (HCAP-G and STK6), mitotic spindle checkpoint (BUB1), inhibition (BIRC5) or stimulation (GPR105) of apoptosis, DNA replication (TOP2A, RRM2, TYMS, PCNA, MCM4 and MCM6), stress response (GLRX2, DNAJA1, HSPA4, HSPA5, HSPD1 and TXNIP), ubiquitin cycle (SIP), actin and calmodulin binding (CNN3), intracellular signalling (STMN2), negative regulation of the Wnt signaling pathway (CTNNBIP1), inhibition of MITF expression (EMX2), regulation of proteolysis (TNA), testis cancer (CML66) and metastasis suppression (NME1). Winnepenninckx et&#xA0;al. [<xref ref-type="bibr" rid="CR92">92</xref>] recommend the use of a battery of antibodies that may improve the future determination of prognosis and treatment stratification. The determination of karyopherin-alpha2, MCMs (minichromosome maintenance proteins), geminin and PCNA over-expression could be used for screening in melanoma patients with a poor clinical outcome.</p>
      </sec>
    </sec>
    <sec id="Sec5">
      <title>Squamous cell carcinoma of the skin</title>
      <p>While primary cutaneous squamous cell carcinomas (SCC) are usually easily treatable, they have the potential to recur locally and even metastasize, then leading to a significant morbidity and mortality. Therefore, it is important to identify those tumours that are more aggressive and require closer follow-up and additional treatments, such as lymph adenectomy or radiation therapy. Established prognostic factors include anatomic site of primary, tumour size, depth of invasion, rapid growth, grade of differentiation, perineural invasion, history of previous treatment, host immunosuppression, and etiologic factors such as burn scars, radiation and chronic ulceration. The histological subtypes of SCC have also been considered as a factor in determining the prognosis [<xref ref-type="bibr" rid="CR60">60</xref>].</p>
      <p>Only few molecular markers are known to be associated with progression or prognosis of cutaneous SCC. In the following, we give an overview on some recently described proteins whose abnormal expression contributes to a malignant phenotype in this cancer entity. STAT3, a member of the signal transducer and activator of transcription (STAT) family of transcription factors is a known regulator of cell motility. The expression of phosphorylated STAT3 (p-STAT3) was described to be stronger in poorly differentiated than in well-differentiated SCCs. Moreover, the percentage of tumour cells expressing p-STAT3 correlated with the depth of tumour invasion and with metastasis formation [<xref ref-type="bibr" rid="CR76">76</xref>].</p>
      <p>E-Cadherin is a Ca(2+)-dependent, intercellular adhesion molecule that is specifically expressed in epithelial cells and tissues and functions by maintaining intercellular connections. In some types of carcinomas, E-cadherin expression of tumour cells is decreased in association with metastasis. In cutaneous SCC, a decreased expression of E-cadherin in the primary lesion is correlated with the development of regional lymph node metastasis [<xref ref-type="bibr" rid="CR41">41</xref>]. Additionally, a decreased expression is more often associated with well-differentiated than with poorly differentiated SCC. Therefore, E-cadherin might be useful as a marker for the metastatic potential of well-differentiated SCC [<xref ref-type="bibr" rid="CR41">41</xref>]. The simultaneous detection of p-STAT3 and E-cadherin may contribute to the prediction of prognosis of cutaneous SCC patients [<xref ref-type="bibr" rid="CR76">76</xref>].</p>
      <p>Another marker to distinguish between well-differentiated and poorly differentiated SCC is Ets-1 [<xref ref-type="bibr" rid="CR37">37</xref>]. Ets-1 is a transcription factor regulating the expression of various genes including matrix metalloproteinases (MMPs). Therefore, Ets-1 might be important in the pathogenesis of invasive SCC. MMP-12 was found to be expressed by tumour cells in squamous cell carcinoma of the vulva. Its expression correlates with invasiveness, while that of macrophages predict a better clinical outcome [<xref ref-type="bibr" rid="CR38">38</xref>]. A cell surface marker, CD44, is a glycoprotein widely distributed in the extracellular matrix. CD44 isoforms, which arise from alternative mRNA splicing, were found to be implicated in the formation of tumour metastasis. In a study by Rodriguez-Rodriguez et&#xA0;al., it was shown that lymph node metastases of cutaneous SCC of the vulva were immunoreactive for CD44&#x2013;9v [<xref ref-type="bibr" rid="CR64">64</xref>]. Also, CD44&#x2013;10v expression was present in 78% of tumours compared to only 56% of normal epithelium. CD44&#x2013;10v membrane expression, but not cytoplasmic expression, correlates with disease recurrence [<xref ref-type="bibr" rid="CR64">64</xref>]. In ocular squamous cell carcinomas, over-expression of CD44&#x2013;6v is correlated with tumour progression and metastasis [<xref ref-type="bibr" rid="CR55">55</xref>].</p>
    </sec>
    <sec id="Sec6">
      <title>Cutaneous T-cell lymphomas</title>
      <p>Cutaneous T-cell lymphomas (CTCL) are a heterogeneous group of cutaneous non-Hodgkin&#x2019;s lymphomas. In this cutaneous malignancy, the tumour cells home to and persist in the skin, producing a broad spectrum of clinical entities. The prognosis of CTCL depends on histologic and molecular aspects. The new WHO/EORTC classification for cutaneous lymphomas comprises mature T-cell and natural killer (NK)-cell lymphomas, mature B-cell lymphomas and immature haematopoietic malignancies. Marker proteins for the diagnosis of CTCL include, for example, CD2, CD3, CD4, CD5, CD7, CD8, CD14, CD16/56, CD19, CD25, CD45, CD45RA and CD45R0 [<xref ref-type="bibr" rid="CR90">90</xref>].</p>
      <p>The probability of survival in CTCL can be accurately predicted by a formula based on the clinical CTCL-Severity-Index (CTCL-SI) [<xref ref-type="bibr" rid="CR20">20</xref>], which evaluates the involvement of the skin, lymph nodes, blood and visceral organs [<xref ref-type="bibr" rid="CR40">40</xref>]. Besides clinical and morphological parameters, several molecules have been investigated in CTCL that are involved in general cellular signalling processes, regulation of cellular proliferation and apoptosis, like Jun, Myc, c-myb, p53, STATs, bcl-2, Fas/CD95 and SOCS-3, or contribute to the putative immunopathology of the disease such as expression of inhibitory MHC receptors (ILT2/CD85j), NK receptors (p140/KIR3DL2) and dendritic cell defects (CD40). The abnormal expression of these molecules could be relevant for the prognosis of CTCL, as it has been shown for other tumour entities [<xref ref-type="bibr" rid="CR39">39</xref>].</p>
      <p>With regard to serological biomarkers in CTCL, it has been shown that the serum concentrations of the soluble alpha-chain of the interleukin-2 receptor (sIL-2R) as well as lactate dehydrogenase (LDH) strongly correlate with lymph node size, but only sIL-2R significantly correlates with the severity of skin manifestations in erythrodermic patients [<xref ref-type="bibr" rid="CR86">86</xref>]. Moreover, sIL-2R was demonstrated to be produced at a relatively low rate by tissue-based lymphoma cells, whereas large-cell transformation in CTCL results in a marked increase in the sIL-2R production in some patients [<xref ref-type="bibr" rid="CR86">86</xref>]. In addition to sIL-2R, neopterin and beta2-microglobulin have been shown to be significantly elevated in the serum from patients with Sezary syndrome. Thus, sIL-2R seems to be the most sensitive marker, which is typically increased in Sezary syndrome. Concerning the outcome of the disease, in terms of disease progression versus non-progression, only neopterin showed a significant prognostic value in non-leukemic CTCL patients [<xref ref-type="bibr" rid="CR31">31</xref>].</p>
    </sec>
    <sec id="Sec7">
      <title>Conclusion and future directions</title>
      <p>Taken together, molecular markers provide additional and much more detailed information for the prognostic classification of cutaneous malignancies. Currently, this is particularly true for malignant melanoma, but will certainly also affect other entities in due time. In addition to the serological and immunhistochemical biomarkers discussed here, genetic abnormalities have recently been recognized to influence the prognosis of cancer patients in higher extents than previously assumed. With regard to malignant melanoma, a new classification system was proposed combining genetic aberrations with histomorphological changes, resulting in new insights into the pathogenesis of this malignancy [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. It may be expected that the rapidly increasing knowledge of molecular mechanisms would lead to mainly biomarker-based, rather than morphology-based, classification systems that might facilitate an individualized, molecular-driven cancer therapy.</p>
    </sec>
  </body>
  <back>
    <ack>
      <p>This work was supported by a grant from the German Cancer Aid/Deutsche Krebshilfe (Proposal No. 106856).</p>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Acland</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Evans</surname>
              <given-names>AV</given-names>
            </name>
            <name>
              <surname>Abraha</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Healy</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Roblin</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Calonje</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Orchard</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Higgins</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Sherwood</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Russell-Jones</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Serum S100 concentrations are not useful in predicting micrometastatic disease in cutaneous malignant melanoma</article-title>
          <source>Br J Dermatol</source>
          <year>2002</year>
          <volume>146</volume>
          <fpage>832</fpage>
          <lpage>835</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1365-2133.2002.04691.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Acland K, Evans AV, Abraha H, Healy CM, Roblin P, Calonje E, Orchard G, Higgins E, Sherwood R, Russell-Jones R (2002) Serum S100 concentrations are not useful in predicting micrometastatic disease in cutaneous malignant melanoma. Br J Dermatol 146:832&#x2013;835 <pub-id pub-id-type="pmid">12000380</pub-id></citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Agrup</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Carstam</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Wittbjer</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Rorsman</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Rosengren</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Tyrosinase activity in serum from patients with malignant melanoma</article-title>
          <source>Acta Derm Venereol</source>
          <year>1989</year>
          <volume>69</volume>
          <fpage>120</fpage>
          <lpage>124</lpage>
        </citation>
        <citation citation-type="display-unstructured">Agrup P, Carstam R, Wittbjer A, Rorsman H, Rosengren E (1989) Tyrosinase activity in serum from patients with malignant melanoma. Acta Derm Venereol 69:120&#x2013;124 <pub-id pub-id-type="pmid">2564228</pub-id></citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Alonso</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Ortiz</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Pollan</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Perez-Gomez</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Sanchez</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Acuna</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Pajares</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Martinez-Tello</surname>
              <given-names>FJ</given-names>
            </name>
            <name>
              <surname>Hortelano</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Piris</surname>
              <given-names>MA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study</article-title>
          <source>Am J Pathol</source>
          <year>2004</year>
          <volume>164</volume>
          <fpage>193</fpage>
          <lpage>203</lpage>
        </citation>
        <citation citation-type="display-unstructured">Alonso SR, Ortiz P, Pollan M, Perez-Gomez B, Sanchez L, Acuna MJ, Pajares R, Martinez-Tello FJ, Hortelano CM, Piris MA, et al (2004) Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study. Am J Pathol 164:193&#x2013;203 <pub-id pub-id-type="pmid">14695333</pub-id></citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Andersen</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Nesland</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Holm</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Florenes</surname>
              <given-names>VA</given-names>
            </name>
            <name>
              <surname>Fodstad</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Maelandsmo</surname>
              <given-names>GM</given-names>
            </name>
          </person-group>
          <article-title>Expression of S100A4 combined with reduced E-cadherin expression predicts patient outcome in malignant melanoma</article-title>
          <source>Mod Pathol</source>
          <year>2004</year>
          <volume>17</volume>
          <fpage>990</fpage>
          <lpage>997</lpage>
          <pub-id pub-id-type="doi">10.1038/modpathol.3800151</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Andersen K, Nesland JM, Holm R, Florenes VA, Fodstad O, Maelandsmo GM (2004) Expression of S100A4 combined with reduced E-cadherin expression predicts patient outcome in malignant melanoma. Mod Pathol 17:990&#x2013;997 <pub-id pub-id-type="pmid">15133476</pub-id></citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bachmann</surname>
              <given-names>IM</given-names>
            </name>
            <name>
              <surname>Straume</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Puntervoll</surname>
              <given-names>HE</given-names>
            </name>
            <name>
              <surname>Kalvenes</surname>
              <given-names>MB</given-names>
            </name>
            <name>
              <surname>Akslen</surname>
              <given-names>LA</given-names>
            </name>
          </person-group>
          <article-title>Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma</article-title>
          <source>Clin Cancer Res</source>
          <year>2005</year>
          <volume>11</volume>
          <fpage>8606</fpage>
          <lpage>8614</lpage>
          <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-05-0011</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Bachmann IM, Straume O, Puntervoll HE, Kalvenes MB, Akslen LA (2005) Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma. Clin Cancer Res 11:8606&#x2013;8614 <pub-id pub-id-type="pmid">16361544</pub-id></citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Balch</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Buzaid</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Soong</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Atkins</surname>
              <given-names>MB</given-names>
            </name>
            <name>
              <surname>Cascinelli</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Coit</surname>
              <given-names>DG</given-names>
            </name>
            <name>
              <surname>Fleming</surname>
              <given-names>ID</given-names>
            </name>
            <name>
              <surname>Gershenwald</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Houghton</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kirkwood</surname>
              <given-names>JM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma</article-title>
          <source>J Clin Oncol</source>
          <year>2001</year>
          <volume>19</volume>
          <fpage>3635</fpage>
          <lpage>3648</lpage>
        </citation>
        <citation citation-type="display-unstructured">Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A Jr, Kirkwood JM, et al (2001) Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19:3635&#x2013;3648 <pub-id pub-id-type="pmid">11504745</pub-id></citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Berger</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Davis</surname>
              <given-names>DW</given-names>
            </name>
            <name>
              <surname>Tellez</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Prieto</surname>
              <given-names>VG</given-names>
            </name>
            <name>
              <surname>Gershenwald</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Rimm</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Bar-Eli</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Automated quantitative analysis of activator protein-2alpha subcellular expression in melanoma tissue microarrays correlates with survival prediction</article-title>
          <source>Cancer Res</source>
          <year>2005</year>
          <volume>65</volume>
          <fpage>11185</fpage>
          <lpage>11192</lpage>
          <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-2300</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Berger AJ, Davis DW, Tellez C, Prieto VG, Gershenwald JE, Johnson MM, Rimm DL, Bar-Eli M (2005) Automated quantitative analysis of activator protein-2alpha subcellular expression in melanoma tissue microarrays correlates with survival prediction. Cancer Res 65:11185&#x2013;11192 <pub-id pub-id-type="pmid">16322269</pub-id></citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Blesch</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Bosserhoff</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Apfel</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Behl</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Hessdoerfer</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Schmitt</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Jachimczak</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Lottspeich</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Buettner</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Bogdahn</surname>
              <given-names>U</given-names>
            </name>
          </person-group>
          <article-title>Cloning of a novel malignant melanoma-derived growth-regulatory protein, MIA</article-title>
          <source>Cancer Res</source>
          <year>1994</year>
          <volume>54</volume>
          <fpage>5695</fpage>
          <lpage>5701</lpage>
        </citation>
        <citation citation-type="display-unstructured">Blesch A, Bosserhoff AK, Apfel R, Behl C, Hessdoerfer B, Schmitt A, Jachimczak P, Lottspeich F, Buettner R, Bogdahn U (1994) Cloning of a novel malignant melanoma-derived growth-regulatory protein, MIA. Cancer Res 54:5695&#x2013;5701 <pub-id pub-id-type="pmid">7923218</pub-id></citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bogdahn</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Apfel</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Hahn</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gerlach</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Behl</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Hoppe</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Martin</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Autocrine tumor cell growth-inhibiting activities from human malignant melanoma</article-title>
          <source>Cancer Res</source>
          <year>1989</year>
          <volume>49</volume>
          <fpage>5358</fpage>
          <lpage>5363</lpage>
        </citation>
        <citation citation-type="display-unstructured">Bogdahn U, Apfel R, Hahn M, Gerlach M, Behl C, Hoppe J, Martin R (1989) Autocrine tumor cell growth-inhibiting activities from human malignant melanoma. Cancer Res 49:5358&#x2013;5363 <pub-id pub-id-type="pmid">2766302</pub-id></citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bosserhoff</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Kaufmann</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kaluza</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Bartke</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Zirngibl</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Hein</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Stolz</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Buettner</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Melanoma-inhibitory activity, a novel serum marker for progression of malignant melanoma</article-title>
          <source>Cancer Res</source>
          <year>1997</year>
          <volume>57</volume>
          <fpage>3149</fpage>
          <lpage>3153</lpage>
        </citation>
        <citation citation-type="display-unstructured">Bosserhoff AK, Kaufmann M, Kaluza B, Bartke I, Zirngibl H, Hein R, Stolz W, Buettner R (1997) Melanoma-inhibitory activity, a novel serum marker for progression of malignant melanoma. Cancer Res 57:3149&#x2013;3153 <pub-id pub-id-type="pmid">9242442</pub-id></citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Boyano</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Garcia-Vazquez</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Lopez-Michelena</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Gardeazabal</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Bilbao</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Canavate</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Galdeano</surname>
              <given-names>AG</given-names>
            </name>
            <name>
              <surname>Izu</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Diaz-Ramon</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Raton</surname>
              <given-names>JA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Soluble interleukin-2 receptor, intercellular adhesion molecule-1 and interleukin-10 serum levels in patients with melanoma</article-title>
          <source>Br J Cancer</source>
          <year>2000</year>
          <volume>83</volume>
          <fpage>847</fpage>
          <lpage>852</lpage>
          <pub-id pub-id-type="doi">10.1054/bjoc.2000.1402</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Boyano MD, Garcia-Vazquez MD, Lopez-Michelena T, Gardeazabal J, Bilbao J, Canavate ML, Galdeano AG, Izu R, Diaz-Ramon L, Raton JA, et al (2000) Soluble interleukin-2 receptor, intercellular adhesion molecule-1 and interleukin-10 serum levels in patients with melanoma. Br J Cancer 83:847&#x2013;852 <pub-id pub-id-type="pmid">10970683</pub-id></citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brennecke</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Deichmann</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Naeher</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kurzen</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Decline in angiogenic factors, such as interleukin-8, indicates response to chemotherapy of metastatic melanoma</article-title>
          <source>Melanoma Res</source>
          <year>2005</year>
          <volume>15</volume>
          <fpage>515</fpage>
          <lpage>522</lpage>
          <pub-id pub-id-type="doi">10.1097/00008390-200512000-00006</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Brennecke S, Deichmann M, Naeher H, Kurzen H (2005) Decline in angiogenic factors, such as interleukin-8, indicates response to chemotherapy of metastatic melanoma. Melanoma Res 15:515&#x2013;522 <pub-id pub-id-type="pmid">16314737</pub-id></citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Carvalho</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Lipay</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Belfort</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Santos</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Andrade</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Haddad</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Brunstein</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Ferreira</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Telomerase activity in prognostic histopathologic features of melanoma</article-title>
          <source>J Plast Reconstr Aesthet Surg</source>
          <year>2006</year>
          <volume>59</volume>
          <fpage>961</fpage>
          <lpage>968</lpage>
          <pub-id pub-id-type="doi">10.1016/j.bjps.2006.01.022</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Carvalho L, Lipay M, Belfort F, Santos I, Andrade J, Haddad A, Brunstein F, Ferreira L (2006) Telomerase activity in prognostic histopathologic features of melanoma. J Plast Reconstr Aesthet Surg 59:961&#x2013;968 <pub-id pub-id-type="pmid">16920589</pub-id></citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Curtin</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Busam</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Pinkel</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Bastian</surname>
              <given-names>BC</given-names>
            </name>
          </person-group>
          <article-title>Somatic Activation of KIT in Distinct Subtypes of Melanoma</article-title>
          <source>J Clin Oncol</source>
          <year>2006</year>
          <volume>14</volume>
          <fpage>14</fpage>
        </citation>
        <citation citation-type="display-unstructured">Curtin JA, Busam K, Pinkel D, Bastian BC (2006) Somatic Activation of KIT in Distinct Subtypes of Melanoma. J Clin Oncol 14:14 </citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Curtin</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Fridlyand</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kageshita</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Patel</surname>
              <given-names>HN</given-names>
            </name>
            <name>
              <surname>Busam</surname>
              <given-names>KJ</given-names>
            </name>
            <name>
              <surname>Kutzner</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Cho</surname>
              <given-names>KH</given-names>
            </name>
            <name>
              <surname>Aiba</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Brocker</surname>
              <given-names>EB</given-names>
            </name>
            <name>
              <surname>LeBoit</surname>
              <given-names>PE</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Distinct sets of genetic alterations in melanoma</article-title>
          <source>N Engl J Med</source>
          <year>2005</year>
          <volume>353</volume>
          <fpage>2135</fpage>
          <lpage>2147</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa050092</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, Cho KH, Aiba S, Brocker EB, LeBoit PE, et al (2005) Distinct sets of genetic alterations in melanoma. N Engl J Med 353:2135&#x2013;2147 <pub-id pub-id-type="pmid">16291983</pub-id></citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dadras</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Paul</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Bertoncini</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>LF</given-names>
            </name>
            <name>
              <surname>Muzikansky</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Jackson</surname>
              <given-names>DG</given-names>
            </name>
            <name>
              <surname>Ellwanger</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Garbe</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Mihm</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Detmar</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival</article-title>
          <source>Am J Pathol</source>
          <year>2003</year>
          <volume>162</volume>
          <fpage>1951</fpage>
          <lpage>1960</lpage>
        </citation>
        <citation citation-type="display-unstructured">Dadras SS, Paul T, Bertoncini J, Brown LF, Muzikansky A, Jackson DG, Ellwanger U, Garbe C, Mihm MC, Detmar M (2003) Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival. Am J Pathol 162:1951&#x2013;1960 <pub-id pub-id-type="pmid">12759251</pub-id></citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dai</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Martinka</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases</article-title>
          <source>J Clin Oncol</source>
          <year>2005</year>
          <volume>23</volume>
          <fpage>1473</fpage>
          <lpage>1482</lpage>
          <pub-id pub-id-type="doi">10.1200/JCO.2005.07.168</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Dai DL, Martinka M, Li G (2005) Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases. J Clin Oncol 23:1473&#x2013;1482 <pub-id pub-id-type="pmid">15735123</pub-id></citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Deichmann</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Brenner</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Bock</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>J&#xE4;ckel</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Uhl</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Waldmann</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>N&#xE4;her</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>S100-beta, melanoma-inhibiting activity and lactate dehydrogenase discriminate progressive from non-progressive American Joint Committee on Cancer stage IV melanoma</article-title>
          <source>J Clin Oncol</source>
          <year>1999</year>
          <volume>17</volume>
          <fpage>1891</fpage>
          <lpage>1896</lpage>
        </citation>
        <citation citation-type="display-unstructured">Deichmann M, Brenner A, Bock M, J&#xE4;ckel A, Uhl K, Waldmann V, N&#xE4;her H (1999) S100-beta, melanoma-inhibiting activity and lactate dehydrogenase discriminate progressive from non-progressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol 17:1891&#x2013;1896 <pub-id pub-id-type="pmid">10561230</pub-id></citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Deichmann</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kahle</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Moser</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Wacker</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Wust</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Diagnosing melanoma patients entering American Joint Committee on Cancer stage IV, C-reactive protein in serum is superior to lactate dehydrogenase</article-title>
          <source>Br J Cancer</source>
          <year>2004</year>
          <volume>91</volume>
          <fpage>699</fpage>
          <lpage>702</lpage>
        </citation>
        <citation citation-type="display-unstructured">Deichmann M, Kahle B, Moser K, Wacker J, Wust K (2004) Diagnosing melanoma patients entering American Joint Committee on Cancer stage IV, C-reactive protein in serum is superior to lactate dehydrogenase. Br J Cancer 91:699&#x2013;702 <pub-id pub-id-type="pmid">15280926</pub-id></citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dippel</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Goerdt</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Assaf</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Stein</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Orfanos</surname>
              <given-names>CE</given-names>
            </name>
          </person-group>
          <article-title>Cutaneous T-cell lymphoma severity index and T-cell gene rearrangement</article-title>
          <source>Lancet</source>
          <year>1997</year>
          <volume>350</volume>
          <fpage>1776</fpage>
          <lpage>1777</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(05)63605-7</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Dippel E, Goerdt S, Assaf C, Stein H, Orfanos CE (1997) Cutaneous T-cell lymphoma severity index and T-cell gene rearrangement. Lancet 350:1776&#x2013;1777 <pub-id pub-id-type="pmid">9413486</pub-id></citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dummer</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Becker</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Schwaaf</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Leverkus</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Moll</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Brocker</surname>
              <given-names>EB</given-names>
            </name>
          </person-group>
          <article-title>Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma</article-title>
          <source>Melanoma Res</source>
          <year>1995</year>
          <volume>5</volume>
          <fpage>67</fpage>
          <lpage>68</lpage>
          <pub-id pub-id-type="doi">10.1097/00008390-199502000-00008</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Dummer W, Becker JC, Schwaaf A, Leverkus M, Moll T, Brocker EB (1995) Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma. Melanoma Res 5:67&#x2013;68 <pub-id pub-id-type="pmid">7734958</pub-id></citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Duncan</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Deeds</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Hunter</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Shao</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Holmgren</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Woolf</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Tepper</surname>
              <given-names>RI</given-names>
            </name>
            <name>
              <surname>Shyjan</surname>
              <given-names>AW</given-names>
            </name>
          </person-group>
          <article-title>Down-regulation of the novel gene melastatin correlates with potential for melanoma metastasis</article-title>
          <source>Cancer Res</source>
          <year>1998</year>
          <volume>58</volume>
          <fpage>1515</fpage>
          <lpage>1520</lpage>
        </citation>
        <citation citation-type="display-unstructured">Duncan LM, Deeds J, Hunter J, Shao J, Holmgren LM, Woolf EA, Tepper RI, Shyjan AW (1998) Down-regulation of the novel gene melastatin correlates with potential for melanoma metastasis. Cancer Res 58:1515&#x2013;1520 <pub-id pub-id-type="pmid">9537257</pub-id></citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fecker</surname>
              <given-names>LF</given-names>
            </name>
            <name>
              <surname>Geilen</surname>
              <given-names>CC</given-names>
            </name>
            <name>
              <surname>Tchernev</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Trefzer</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Assaf</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Kurbanov</surname>
              <given-names>BM</given-names>
            </name>
            <name>
              <surname>Schwarz</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Daniel</surname>
              <given-names>PT</given-names>
            </name>
            <name>
              <surname>Eberle</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Loss of proapoptotic Bcl-2-related multidomain proteins in primary melanomas is associated with poor prognosis</article-title>
          <source>J Invest Dermatol</source>
          <year>2006</year>
          <volume>126</volume>
          <fpage>1366</fpage>
          <lpage>1371</lpage>
          <pub-id pub-id-type="doi">10.1038/sj.jid.5700192</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Fecker LF, Geilen CC, Tchernev G, Trefzer U, Assaf C, Kurbanov BM, Schwarz C, Daniel PT, Eberle J (2006) Loss of proapoptotic Bcl-2-related multidomain proteins in primary melanomas is associated with poor prognosis. J Invest Dermatol 126:1366&#x2013;1371 <pub-id pub-id-type="pmid">16528364</pub-id></citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Florenes</surname>
              <given-names>VA</given-names>
            </name>
            <name>
              <surname>Faye</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Maelandsmo</surname>
              <given-names>GM</given-names>
            </name>
            <name>
              <surname>Nesland</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Holm</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Levels of cyclin D1 and D3 in malignant melanoma: deregulated cyclin D3 expression is associated with poor clinical outcome in superficial melanoma</article-title>
          <source>Clin Cancer Res</source>
          <year>2000</year>
          <volume>6</volume>
          <fpage>3614</fpage>
          <lpage>3620</lpage>
        </citation>
        <citation citation-type="display-unstructured">Florenes VA, Faye RS, Maelandsmo GM, Nesland JM, Holm R (2000) Levels of cyclin D1 and D3 in malignant melanoma: deregulated cyclin D3 expression is associated with poor clinical outcome in superficial melanoma. Clin Cancer Res 6:3614&#x2013;3620 <pub-id pub-id-type="pmid">10999753</pub-id></citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Florenes</surname>
              <given-names>VA</given-names>
            </name>
            <name>
              <surname>Maelandsmo</surname>
              <given-names>GM</given-names>
            </name>
            <name>
              <surname>Faye</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Nesland</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Holm</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Cyclin a expression in superficial spreading malignant melanomas correlates with clinical outcome</article-title>
          <source>J Pathol</source>
          <year>2001</year>
          <volume>195</volume>
          <fpage>530</fpage>
          <lpage>536</lpage>
          <pub-id pub-id-type="doi">10.1002/path.1007</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Florenes VA, Maelandsmo GM, Faye R, Nesland JM, Holm R (2001) Cyclin a expression in superficial spreading malignant melanomas correlates with clinical outcome. J Pathol 195:530&#x2013;536 <pub-id pub-id-type="pmid">11745687</pub-id></citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Franzke</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Probst-Kepper</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Buer</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Duensing</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hoffmann</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Wittke</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Volkenandt</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ganser</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Atzpodien</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma</article-title>
          <source>Br J Cancer</source>
          <year>1998</year>
          <volume>78</volume>
          <fpage>40</fpage>
          <lpage>45</lpage>
        </citation>
        <citation citation-type="display-unstructured">Franzke A, Probst-Kepper M, Buer J, Duensing S, Hoffmann R, Wittke F, Volkenandt M, Ganser A, Atzpodien J (1998) Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma. Br J Cancer 78:40&#x2013;45 <pub-id pub-id-type="pmid">9662248</pub-id></citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fujimoto</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Takeuchi</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Taback</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Hsueh</surname>
              <given-names>EC</given-names>
            </name>
            <name>
              <surname>Elashoff</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Morton</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Hoon</surname>
              <given-names>DS</given-names>
            </name>
          </person-group>
          <article-title>Allelic imbalance of 12q22&#x2013;23 associated with APAF-1 locus correlates with poor disease outcome in cutaneous melanoma</article-title>
          <source>Cancer Res</source>
          <year>2004</year>
          <volume>64</volume>
          <fpage>2245</fpage>
          <lpage>2250</lpage>
          <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-03-2932</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Fujimoto A, Takeuchi H, Taback B, Hsueh EC, Elashoff D, Morton DL, Hoon DS (2004) Allelic imbalance of 12q22&#x2013;23 associated with APAF-1 locus correlates with poor disease outcome in cutaneous melanoma. Cancer Res 64:2245&#x2013;2250 <pub-id pub-id-type="pmid">15026369</pub-id></citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Garbe</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Leiter</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Ellwanger</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Blaheta</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>Meier</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Rassner</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Schittek</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients</article-title>
          <source>Cancer</source>
          <year>2003</year>
          <volume>97</volume>
          <fpage>1737</fpage>
          <lpage>1745</lpage>
          <pub-id pub-id-type="doi">10.1002/cncr.11250</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Garbe C, Leiter U, Ellwanger U, Blaheta HJ, Meier F, Rassner G, Schittek B (2003) Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients. Cancer 97:1737&#x2013;1745 <pub-id pub-id-type="pmid">12655531</pub-id></citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gimotty</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Belle</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Elder</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Murry</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Montone</surname>
              <given-names>KT</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Hotz</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Raines</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ming</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Wahl</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma</article-title>
          <source>J Clin Oncol</source>
          <year>2005</year>
          <volume>23</volume>
          <fpage>8048</fpage>
          <lpage>8056</lpage>
          <pub-id pub-id-type="doi">10.1200/JCO.2005.02.0735</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Gimotty PA, Van Belle P, Elder DE, Murry T, Montone KT, Xu X, Hotz S, Raines S, Ming ME, Wahl P, et al (2005) Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma. J Clin Oncol 23:8048&#x2013;8056 <pub-id pub-id-type="pmid">16258103</pub-id></citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Guo</surname>
              <given-names>HB</given-names>
            </name>
            <name>
              <surname>Stoffel-Wagner</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Bierwirth</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Mezger</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Klingmuller</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Clinical significance of serum S100 in metastatic malignant melanoma</article-title>
          <source>Eur J Cancer</source>
          <year>1995</year>
          <volume>31A</volume>
          <fpage>924</fpage>
          <lpage>928</lpage>
          <pub-id pub-id-type="doi">10.1016/0959-8049(95)00087-9</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Guo HB, Stoffel-Wagner B, Bierwirth T, Mezger J, Klingmuller D (1995) Clinical significance of serum S100 in metastatic malignant melanoma. Eur J Cancer 31A:924&#x2013;928 <pub-id pub-id-type="pmid">7646923</pub-id></citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hassel</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Meier</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Joller-Jemelka</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Burg</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Dummer</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Serological immunomarkers in cutaneous T cell lymphoma</article-title>
          <source>Dermatology</source>
          <year>2004</year>
          <volume>209</volume>
          <fpage>296</fpage>
          <lpage>300</lpage>
          <pub-id pub-id-type="doi">10.1159/000080852</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Hassel JC, Meier R, Joller-Jemelka H, Burg G, Dummer R (2004) Serological immunomarkers in cutaneous T cell lymphoma. Dermatology 209:296&#x2013;300 <pub-id pub-id-type="pmid">15539892</pub-id></citation>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hauschild</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Engel</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Brenner</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Glaeser</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Moenig</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Henze</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Christophers</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Predictive value of serum S100B for monitoring patients with metastatic melanoma during chemotherapy and/or immunotherapy</article-title>
          <source>Br J Dermatol</source>
          <year>1999a</year>
          <volume>140</volume>
          <fpage>1065</fpage>
          <lpage>1071</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1365-2133.1999.02905.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Hauschild A, Engel G, Brenner W, Glaeser R, Moenig H, Henze E, Christophers E (1999a) Predictive value of serum S100B for monitoring patients with metastatic melanoma during chemotherapy and/or immunotherapy. Br J Dermatol 140:1065&#x2013;1071 <pub-id pub-id-type="pmid">10354072</pub-id></citation>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hauschild</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Engel</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Brenner</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Glaeser</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Monig</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Henze</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Christophers</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>S100B protein detection in serum is a significant prognostic factor in metastatic melanoma</article-title>
          <source>Oncology</source>
          <year>1999b</year>
          <volume>56</volume>
          <fpage>338</fpage>
          <lpage>344</lpage>
          <pub-id pub-id-type="doi">10.1159/000011989</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Hauschild A, Engel G, Brenner W, Glaeser R, Monig H, Henze E, Christophers E (1999b) S100B protein detection in serum is a significant prognostic factor in metastatic melanoma. Oncology 56:338&#x2013;344 <pub-id pub-id-type="pmid">10343200</pub-id></citation>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hirai</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kageshita</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kimura</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Tsujisaki</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Imai</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Wakamatsu</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ito</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ono</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Serum levels of sICAM-1 and 5-S-cysteinyldopa as markers of melanoma progression</article-title>
          <source>Melanoma Res</source>
          <year>1997</year>
          <volume>7</volume>
          <fpage>58</fpage>
          <lpage>62</lpage>
          <pub-id pub-id-type="doi">10.1097/00008390-199702000-00009</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Hirai S, Kageshita T, Kimura T, Tsujisaki M, Imai K, Wakamatsu K, Ito S, Ono T (1997) Serum levels of sICAM-1 and 5-S-cysteinyldopa as markers of melanoma progression. Melanoma Res 7:58&#x2013;62 <pub-id pub-id-type="pmid">9067966</pub-id></citation>
      </ref>
      <ref id="CR35">
        <label>35.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Janku</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Novotny</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Julis</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Julisova</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Pecen</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Tomancova</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Kocmanova</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Krasna</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Krajsova</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Stork</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>KIT receptor is expressed in more than 50% of early-stage malignant melanoma: a retrospective study of 261 patients</article-title>
          <source>Melanoma Res</source>
          <year>2005</year>
          <volume>15</volume>
          <fpage>251</fpage>
          <lpage>256</lpage>
          <pub-id pub-id-type="doi">10.1097/00008390-200508000-00004</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Janku F, Novotny J, Julis I, Julisova I, Pecen L, Tomancova V, Kocmanova G, Krasna L, Krajsova I, Stork J, et al (2005) KIT receptor is expressed in more than 50% of early-stage malignant melanoma: a retrospective study of 261 patients. Melanoma Res 15:251&#x2013;256 <pub-id pub-id-type="pmid">16034302</pub-id></citation>
      </ref>
      <ref id="CR36">
        <label>36.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jury</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>McAllister</surname>
              <given-names>EJ</given-names>
            </name>
            <name>
              <surname>MacKie</surname>
              <given-names>RM</given-names>
            </name>
          </person-group>
          <article-title>Rising levels of serum S100 protein precede other evidence of disease progression in patients with malignant melanoma</article-title>
          <source>Br J Dermatol</source>
          <year>2000</year>
          <volume>143</volume>
          <fpage>269</fpage>
          <lpage>274</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1365-2133.2000.03650.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Jury CS, McAllister EJ, MacKie RM (2000) Rising levels of serum S100 protein precede other evidence of disease progression in patients with malignant melanoma. Br J Dermatol 143:269&#x2013;274 <pub-id pub-id-type="pmid">10951132</pub-id></citation>
      </ref>
      <ref id="CR37">
        <label>37.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Keehn</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Smoller</surname>
              <given-names>BR</given-names>
            </name>
            <name>
              <surname>Morgan</surname>
              <given-names>MB</given-names>
            </name>
          </person-group>
          <article-title>Ets-1 immunohistochemical expression in non-melanoma skin carcinoma</article-title>
          <source>J Cutan Pathol</source>
          <year>2004</year>
          <volume>31</volume>
          <fpage>8</fpage>
          <lpage>13</lpage>
          <pub-id pub-id-type="doi">10.1046/j.0303-6987.2004.0158.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Keehn CA, Smoller BR, Morgan MB (2004) Ets-1 immunohistochemical expression in non-melanoma skin carcinoma. J Cutan Pathol 31:8&#x2013;13 <pub-id pub-id-type="pmid">14675279</pub-id></citation>
      </ref>
      <ref id="CR38">
        <label>38.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kerkela</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Ala-aho</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Klemi</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Grenman</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Shapiro</surname>
              <given-names>SD</given-names>
            </name>
            <name>
              <surname>Kahari</surname>
              <given-names>VM</given-names>
            </name>
            <name>
              <surname>Saarialho-Kere</surname>
              <given-names>U</given-names>
            </name>
          </person-group>
          <article-title>Metalloelastase (MMP-12) expression by tumour cells in squamous cell carcinoma of the vulva correlates with invasiveness, while that by macrophages predicts better outcome</article-title>
          <source>J Pathol</source>
          <year>2002</year>
          <volume>198</volume>
          <fpage>258</fpage>
          <lpage>269</lpage>
          <pub-id pub-id-type="doi">10.1002/path.1198</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Kerkela E, Ala-aho R, Klemi P, Grenman S, Shapiro SD, Kahari VM, Saarialho-Kere U (2002) Metalloelastase (MMP-12) expression by tumour cells in squamous cell carcinoma of the vulva correlates with invasiveness, while that by macrophages predicts better outcome. J Pathol 198:258&#x2013;269 <pub-id pub-id-type="pmid">12237887</pub-id></citation>
      </ref>
      <ref id="CR39">
        <label>39.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Klemke</surname>
              <given-names>CD</given-names>
            </name>
            <name>
              <surname>Goerdt</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Schrama</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Becker</surname>
              <given-names>JC</given-names>
            </name>
          </person-group>
          <article-title>New insights into the molecular biology and targeted therapy of cutaneous T-cell lymphomas</article-title>
          <source>J Dtsch Dermatol Ges</source>
          <year>2006</year>
          <volume>4</volume>
          <fpage>395</fpage>
          <lpage>406</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1610-0387.2006.05982.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Klemke CD, Goerdt S, Schrama D, Becker JC (2006) New insights into the molecular biology and targeted therapy of cutaneous T-cell lymphomas. J Dtsch Dermatol Ges 4:395&#x2013;406 <pub-id pub-id-type="pmid">16686607</pub-id></citation>
      </ref>
      <ref id="CR40">
        <label>40.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Klemke</surname>
              <given-names>CD</given-names>
            </name>
            <name>
              <surname>Mansmann</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Poenitz</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Dippel</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Goerdt</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Prognostic factors and prediction of prognosis by the CTCL Severity Index in mycosis fungoides and Sezary syndrome</article-title>
          <source>Br J Dermatol</source>
          <year>2005</year>
          <volume>153</volume>
          <fpage>118</fpage>
          <lpage>124</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2133.2005.06676.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Klemke CD, Mansmann U, Poenitz N, Dippel E, Goerdt S (2005) Prognostic factors and prediction of prognosis by the CTCL Severity Index in mycosis fungoides and Sezary syndrome. Br J Dermatol 153:118&#x2013;124 <pub-id pub-id-type="pmid">16029336</pub-id></citation>
      </ref>
      <ref id="CR41">
        <label>41.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Koseki</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Aoki</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ansai</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hozumi</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Mitsuhashi</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Kondo</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>An immunohistochemical study of E-cadherin expression in human squamous cell carcinoma of the skin: relationship between decreased expression of E-cadherin in the primary lesion and regional lymph node metastasis</article-title>
          <source>J Dermatol</source>
          <year>1999</year>
          <volume>26</volume>
          <fpage>416</fpage>
          <lpage>422</lpage>
        </citation>
        <citation citation-type="display-unstructured">Koseki S, Aoki T, Ansai S, Hozumi Y, Mitsuhashi Y, Kondo S (1999) An immunohistochemical study of E-cadherin expression in human squamous cell carcinoma of the skin: relationship between decreased expression of E-cadherin in the primary lesion and regional lymph node metastasis. J Dermatol 26:416&#x2013;422 <pub-id pub-id-type="pmid">10458080</pub-id></citation>
      </ref>
      <ref id="CR42">
        <label>42.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kraehn</surname>
              <given-names>GM</given-names>
            </name>
            <name>
              <surname>Utikal</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Udart</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Greulich</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Bezold</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Kaskel</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Leiter</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Peter</surname>
              <given-names>RU</given-names>
            </name>
          </person-group>
          <article-title>Extra c-myc oncogene copies in high risk cutaneous malignant melanoma and melanoma metastases</article-title>
          <source>Br J Cancer</source>
          <year>2001</year>
          <volume>84</volume>
          <fpage>72</fpage>
          <lpage>79</lpage>
          <pub-id pub-id-type="doi">10.1054/bjoc.2000.1535</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Kraehn GM, Utikal J, Udart M, Greulich KM, Bezold G, Kaskel P, Leiter U, Peter RU (2001) Extra c-myc oncogene copies in high risk cutaneous malignant melanoma and melanoma metastases. Br J Cancer 84:72&#x2013;79 <pub-id pub-id-type="pmid">11139316</pub-id></citation>
      </ref>
      <ref id="CR43">
        <label>43.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kr&#xE4;hn</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Kaskel</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Sander</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Waizenhofer</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Wortmann</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Leiter</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Peter</surname>
              <given-names>RU</given-names>
            </name>
          </person-group>
          <article-title>S100 beta is a more reliable tumor marker in peripheral blood for patients with newly occurred melanoma metastases compared with MIA, albumin and lactate-dehydrogenase</article-title>
          <source>Anticancer Res</source>
          <year>2001</year>
          <volume>21</volume>
          <fpage>1311</fpage>
          <lpage>1316</lpage>
        </citation>
        <citation citation-type="display-unstructured">Kr&#xE4;hn G, Kaskel P, Sander S, Waizenhofer PJ, Wortmann S, Leiter U, Peter RU (2001) S100 beta is a more reliable tumor marker in peripheral blood for patients with newly occurred melanoma metastases compared with MIA, albumin and lactate-dehydrogenase. Anticancer Res 21:1311&#x2013;1316 <pub-id pub-id-type="pmid">11396205</pub-id></citation>
      </ref>
      <ref id="CR44">
        <label>44.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mangini</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Bhawan</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Immunohistochemical markers of melanocytic lesions: a review of their diagnostic usefulness</article-title>
          <source>Am J Dermatopathol</source>
          <year>2002</year>
          <volume>24</volume>
          <fpage>270</fpage>
          <lpage>281</lpage>
          <pub-id pub-id-type="doi">10.1097/00000372-200206000-00016</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Mangini J, Li N, Bhawan J (2002) Immunohistochemical markers of melanocytic lesions: a review of their diagnostic usefulness. Am J Dermatopathol 24:270&#x2013;281 <pub-id pub-id-type="pmid">12140448</pub-id></citation>
      </ref>
      <ref id="CR45">
        <label>45.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Massi</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Franchi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Borgognoni</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Reali</surname>
              <given-names>UM</given-names>
            </name>
            <name>
              <surname>Santucci</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas</article-title>
          <source>Hum Pathol</source>
          <year>1999</year>
          <volume>30</volume>
          <fpage>339</fpage>
          <lpage>344</lpage>
          <pub-id pub-id-type="doi">10.1016/S0046-8177(99)90014-X</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Massi D, Franchi A, Borgognoni L, Reali UM, Santucci M (1999) Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas. Hum Pathol 30:339&#x2013;344 <pub-id pub-id-type="pmid">10088554</pub-id></citation>
      </ref>
      <ref id="CR46">
        <label>46.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mian</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ugurel</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Parkinson</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Schlenzka</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Dryden</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Lancashire</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Ball</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Creaser</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Rees</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Schadendorf</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Serum fingerprinting discriminates between clinical stages and predicts disease progression in melanoma patients</article-title>
          <source>J Clin Oncol</source>
          <year>2005</year>
          <volume>23</volume>
          <fpage>5088</fpage>
          <lpage>5093</lpage>
          <pub-id pub-id-type="doi">10.1200/JCO.2005.03.164</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Mian S, Ugurel S, Parkinson E, Schlenzka I, Dryden I, Lancashire L, Ball G, Creaser C, Rees R, Schadendorf D (2005) Serum fingerprinting discriminates between clinical stages and predicts disease progression in melanoma patients. J Clin Oncol 23:5088&#x2013;5093 <pub-id pub-id-type="pmid">16051955</pub-id></citation>
      </ref>
      <ref id="CR47">
        <label>47.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mihic-Probst</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Mnich</surname>
              <given-names>CD</given-names>
            </name>
            <name>
              <surname>Oberholzer</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Seifert</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Sasse</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Moch</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Dummer</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>p16 expression in primary malignant melanoma is associated with prognosis and lymph node status</article-title>
          <source>Int J Cancer</source>
          <year>2006</year>
          <volume>118</volume>
          <fpage>2262</fpage>
          <lpage>2268</lpage>
          <pub-id pub-id-type="doi">10.1002/ijc.21608</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Mihic-Probst D, Mnich CD, Oberholzer PA, Seifert B, Sasse B, Moch H, Dummer R (2006) p16 expression in primary malignant melanoma is associated with prognosis and lymph node status. Int J Cancer 118:2262&#x2013;2268 <pub-id pub-id-type="pmid">16331607</pub-id></citation>
      </ref>
      <ref id="CR48">
        <label>48.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mikhail</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Velazquez</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Shapiro</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Berman</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Pavlick</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Sorhaindo</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Spira</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Mir</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Panageas</surname>
              <given-names>KS</given-names>
            </name>
            <name>
              <surname>Polsky</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>PTEN expression in melanoma: relationship with patient survival, Bcl-2 expression, and proliferation</article-title>
          <source>Clin Cancer Res</source>
          <year>2005</year>
          <volume>11</volume>
          <fpage>5153</fpage>
          <lpage>5157</lpage>
          <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-05-0397</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Mikhail M, Velazquez E, Shapiro R, Berman R, Pavlick A, Sorhaindo L, Spira J, Mir C, Panageas KS, Polsky D, et al (2005) PTEN expression in melanoma: relationship with patient survival, Bcl-2 expression, and proliferation. Clin Cancer Res 11:5153&#x2013;5157 <pub-id pub-id-type="pmid">16033830</pub-id></citation>
      </ref>
      <ref id="CR49">
        <label>49.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Moore</surname>
              <given-names>BW</given-names>
            </name>
          </person-group>
          <article-title>A soluble protein characteristic of the nervous system</article-title>
          <source>Biochem Biophys Res Commun</source>
          <year>1965</year>
          <volume>19</volume>
          <fpage>739</fpage>
          <lpage>744</lpage>
          <pub-id pub-id-type="doi">10.1016/0006-291X(65)90320-7</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Moore BW (1965) A soluble protein characteristic of the nervous system. Biochem Biophys Res Commun 19:739&#x2013;744 <pub-id pub-id-type="pmid">4953930</pub-id></citation>
      </ref>
      <ref id="CR50">
        <label>50.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mouawad</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Benhammouda</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Rixe</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Antoine</surname>
              <given-names>EC</given-names>
            </name>
            <name>
              <surname>Borel</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Weil</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Khayat</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Soubrane</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Endogenous interleukin 6 levels in patients with metastatic malignant melanoma: correlation with tumor burden</article-title>
          <source>Clin Cancer Res</source>
          <year>1996</year>
          <volume>2</volume>
          <fpage>1405</fpage>
          <lpage>1409</lpage>
        </citation>
        <citation citation-type="display-unstructured">Mouawad R, Benhammouda A, Rixe O, Antoine EC, Borel C, Weil M, Khayat D, Soubrane C (1996) Endogenous interleukin 6 levels in patients with metastatic malignant melanoma: correlation with tumor burden. Clin Cancer Res 2:1405&#x2013;1409 <pub-id pub-id-type="pmid">9816314</pub-id></citation>
      </ref>
      <ref id="CR51">
        <label>51.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nemunaitis</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Fong</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Shabe</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Martineau</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Ando</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Comparison of serum interleukin-10 (IL-10) levels between normal volunteers and patients with advanced melanoma</article-title>
          <source>Cancer Invest</source>
          <year>2001</year>
          <volume>19</volume>
          <fpage>239</fpage>
          <lpage>247</lpage>
          <pub-id pub-id-type="doi">10.1081/CNV-100102550</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Nemunaitis J, Fong T, Shabe P, Martineau D, Ando D (2001) Comparison of serum interleukin-10 (IL-10) levels between normal volunteers and patients with advanced melanoma. Cancer Invest 19:239&#x2013;247 <pub-id pub-id-type="pmid">11338880</pub-id></citation>
      </ref>
      <ref id="CR52">
        <label>52.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Niezabitowski</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Czajecki</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Rys</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kruczak</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gruchala</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Wasilewska</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lackowska</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Sokolowski</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Szklarski</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>Prognostic evaluation of cutaneous malignant melanoma: a clinicopathologic and immunohistochemical study</article-title>
          <source>J Surg Oncol</source>
          <year>1999</year>
          <volume>70</volume>
          <fpage>150</fpage>
          <lpage>160</lpage>
          <pub-id pub-id-type="doi">10.1002/(SICI)1096-9098(199903)70:3&lt;150::AID-JSO2&gt;3.0.CO;2-Z</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Niezabitowski A, Czajecki K, Rys J, Kruczak A, Gruchala A, Wasilewska A, Lackowska B, Sokolowski A, Szklarski W (1999) Prognostic evaluation of cutaneous malignant melanoma: a clinicopathologic and immunohistochemical study. J Surg Oncol 70:150&#x2013;160 <pub-id pub-id-type="pmid">10102344</pub-id></citation>
      </ref>
      <ref id="CR53">
        <label>53.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nikkola</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Vihinen</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Vuoristo</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Kellokumpu-Lehtinen</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Kahari</surname>
              <given-names>VM</given-names>
            </name>
            <name>
              <surname>Pyrhonen</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma</article-title>
          <source>Clin Cancer Res</source>
          <year>2005</year>
          <volume>11</volume>
          <fpage>5158</fpage>
          <lpage>5166</lpage>
          <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-04-2478</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Nikkola J, Vihinen P, Vuoristo MS, Kellokumpu-Lehtinen P, Kahari VM, Pyrhonen S (2005) High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma. Clin Cancer Res 11:5158&#x2013;5166 <pub-id pub-id-type="pmid">16033831</pub-id></citation>
      </ref>
      <ref id="CR54">
        <label>54.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nishizawa</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Nakanishi</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Yoshimura</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Sasajima</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Yamazaki</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Yamamoto</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hanada</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kanai</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Hirohashi</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Clinicopathologic significance of dysadherin expression in cutaneous malignant melanoma: immunohistochemical analysis of 115 patients</article-title>
          <source>Cancer</source>
          <year>2005</year>
          <volume>103</volume>
          <fpage>1693</fpage>
          <lpage>1700</lpage>
          <pub-id pub-id-type="doi">10.1002/cncr.20984</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Nishizawa A, Nakanishi Y, Yoshimura K, Sasajima Y, Yamazaki N, Yamamoto A, Hanada K, Kanai Y, Hirohashi S (2005) Clinicopathologic significance of dysadherin expression in cutaneous malignant melanoma: immunohistochemical analysis of 115 patients. Cancer 103:1693&#x2013;1700 <pub-id pub-id-type="pmid">15751018</pub-id></citation>
      </ref>
      <ref id="CR55">
        <label>55.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Niu</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Zhou</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Expression of CD44V6 and PCNA in squamous cell carcinomas</article-title>
          <source>Chin Med J (Engl)</source>
          <year>2002</year>
          <volume>115</volume>
          <fpage>1564</fpage>
          <lpage>1568</lpage>
        </citation>
        <citation citation-type="display-unstructured">Niu Y, Liu F, Zhou Z, Wang H (2002) Expression of CD44V6 and PCNA in squamous cell carcinomas. Chin Med J (Engl) 115:1564&#x2013;1568 <pub-id pub-id-type="pmid">12490112</pub-id></citation>
      </ref>
      <ref id="CR56">
        <label>56.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Osella-Abate</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Quaglino</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Savoia</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Leporati</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Comessatti</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Bernengo</surname>
              <given-names>MG</given-names>
            </name>
          </person-group>
          <article-title>VEGF-165 serum levels and tyrosinase expression in melanoma patients: correlation with the clinical course</article-title>
          <source>Melanoma Res</source>
          <year>2002</year>
          <volume>12</volume>
          <fpage>325</fpage>
          <lpage>334</lpage>
          <pub-id pub-id-type="doi">10.1097/00008390-200208000-00004</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Osella-Abate S, Quaglino P, Savoia P, Leporati C, Comessatti A, Bernengo MG (2002) VEGF-165 serum levels and tyrosinase expression in melanoma patients: correlation with the clinical course. Melanoma Res 12:325&#x2013;334 <pub-id pub-id-type="pmid">12170181</pub-id></citation>
      </ref>
      <ref id="CR57">
        <label>57.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ostmeier</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Fuchs</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Otto</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Mawick</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Lippold</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Krieg</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Suter</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Prognostic immunohistochemical markers of primary human melanomas</article-title>
          <source>Br J Dermatol</source>
          <year>2001</year>
          <volume>145</volume>
          <fpage>203</fpage>
          <lpage>209</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1365-2133.2001.04335.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Ostmeier H, Fuchs B, Otto F, Mawick R, Lippold A, Krieg V, Suter L (2001) Prognostic immunohistochemical markers of primary human melanomas. Br J Dermatol 145:203&#x2013;209 <pub-id pub-id-type="pmid">11531780</pub-id></citation>
      </ref>
      <ref id="CR58">
        <label>58.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ottaiano</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Leonardi</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Simeone</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Ascierto</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Scala</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Calemma</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Bryce</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Caraco</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Satriano</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Gianfranco</surname>
              <given-names>N</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Soluble interleukin-2 receptor in stage I-III melanoma</article-title>
          <source>Cytokine</source>
          <year>2006</year>
          <volume>33</volume>
          <fpage>150</fpage>
          <lpage>155</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cyto.2006.01.002</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Ottaiano A, Leonardi E, Simeone E, Ascierto PA, Scala S, Calemma R, Bryce J, Caraco C, Satriano RA, Gianfranco N, et al (2006) Soluble interleukin-2 receptor in stage I-III melanoma. Cytokine 33:150&#x2013;155 <pub-id pub-id-type="pmid">16517174</pub-id></citation>
      </ref>
      <ref id="CR59">
        <label>59.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Persson</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Hardemark</surname>
              <given-names>HG</given-names>
            </name>
            <name>
              <surname>Gustafsson</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Rundstrom</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Mendel-Hartvig</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Esscher</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Pahlman</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>S-100 protein and neuron-specific enolase in cerebrospinal fluid and serum: markers of cell damage in human central nervous system</article-title>
          <source>Stroke</source>
          <year>1987</year>
          <volume>18</volume>
          <fpage>911</fpage>
          <lpage>918</lpage>
        </citation>
        <citation citation-type="display-unstructured">Persson L, Hardemark HG, Gustafsson J, Rundstrom G, Mendel-Hartvig I, Esscher T, Pahlman S (1987) S-100 protein and neuron-specific enolase in cerebrospinal fluid and serum: markers of cell damage in human central nervous system. Stroke 18:911&#x2013;918 <pub-id pub-id-type="pmid">3629651</pub-id></citation>
      </ref>
      <ref id="CR60">
        <label>60.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Petter</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Haustein</surname>
              <given-names>UF</given-names>
            </name>
          </person-group>
          <article-title>Histologic subtyping and malignancy assessment of cutaneous squamous cell carcinoma</article-title>
          <source>Dermatol Surg</source>
          <year>2000</year>
          <volume>26</volume>
          <fpage>521</fpage>
          <lpage>530</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1524-4725.2000.99181.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Petter G, Haustein UF (2000) Histologic subtyping and malignancy assessment of cutaneous squamous cell carcinoma. Dermatol Surg 26:521&#x2013;530 <pub-id pub-id-type="pmid">10848931</pub-id></citation>
      </ref>
      <ref id="CR61">
        <label>61.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Polsky</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Melzer</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Hazan</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Panageas</surname>
              <given-names>KS</given-names>
            </name>
            <name>
              <surname>Busam</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Drobnjak</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kamino</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Spira</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Kopf</surname>
              <given-names>AW</given-names>
            </name>
            <name>
              <surname>Houghton</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>HDM2 protein overexpression and prognosis in primary malignant melanoma</article-title>
          <source>J Natl Cancer Inst</source>
          <year>2002</year>
          <volume>94</volume>
          <fpage>1803</fpage>
          <lpage>1806</lpage>
        </citation>
        <citation citation-type="display-unstructured">Polsky D, Melzer K, Hazan C, Panageas KS, Busam K, Drobnjak M, Kamino H, Spira JG, Kopf AW, Houghton A, et al (2002) HDM2 protein overexpression and prognosis in primary malignant melanoma. J Natl Cancer Inst 94:1803&#x2013;1806 <pub-id pub-id-type="pmid">12464652</pub-id></citation>
      </ref>
      <ref id="CR62">
        <label>62.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rebmann</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Ugurel</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Tilgen</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Reinhold</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Grosse-Wilde</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Soluble HLA-DR is a potent predictive indicator of disease progression in serum from early-stage melanoma patients</article-title>
          <source>Int J Cancer</source>
          <year>2002</year>
          <volume>100</volume>
          <fpage>580</fpage>
          <lpage>585</lpage>
          <pub-id pub-id-type="doi">10.1002/ijc.10524</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Rebmann V, Ugurel S, Tilgen W, Reinhold U, Grosse-Wilde H (2002) Soluble HLA-DR is a potent predictive indicator of disease progression in serum from early-stage melanoma patients. Int J Cancer 100:580&#x2013;585 <pub-id pub-id-type="pmid">12124808</pub-id></citation>
      </ref>
      <ref id="CR63">
        <label>63.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Redondo</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Lloret</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Idoate</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Inoges</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Expression and serum levels of MMP-2 and MMP-9 during human melanoma progression</article-title>
          <source>Clin Exp Dermatol</source>
          <year>2005</year>
          <volume>30</volume>
          <fpage>541</fpage>
          <lpage>545</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2230.2005.01849.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Redondo P, Lloret P, Idoate M, Inoges S (2005) Expression and serum levels of MMP-2 and MMP-9 during human melanoma progression. Clin Exp Dermatol 30:541&#x2013;545 <pub-id pub-id-type="pmid">16045689</pub-id></citation>
      </ref>
      <ref id="CR64">
        <label>64.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rodriguez-Rodriguez</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Sancho-Torres</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Gibbon</surname>
              <given-names>DG</given-names>
            </name>
            <name>
              <surname>Watelet</surname>
              <given-names>LF</given-names>
            </name>
            <name>
              <surname>Mesonero</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>CD44&#x2013;9v and CD44-10v are potential molecular markers for squamous cell carcinoma of the vulva</article-title>
          <source>J Soc Gynecol Investig</source>
          <year>2000</year>
          <volume>7</volume>
          <fpage>70</fpage>
          <lpage>75</lpage>
          <pub-id pub-id-type="doi">10.1016/S1071-5576(99)00045-3</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Rodriguez-Rodriguez L, Sancho-Torres I, Gibbon DG, Watelet LF, Mesonero C (2000) CD44&#x2013;9v and CD44-10v are potential molecular markers for squamous cell carcinoma of the vulva. J Soc Gynecol Investig 7:70&#x2013;75 <pub-id pub-id-type="pmid">10732319</pub-id></citation>
      </ref>
      <ref id="CR65">
        <label>65.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Roesch</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Becker</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Meyer</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Wild</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Hafner</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Landthaler</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Vogt</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Retinoblastoma-binding protein 2-homolog 1: a retinoblastoma-binding protein downregulated in malignant melanomas</article-title>
          <source>Mod Pathol</source>
          <year>2005</year>
          <volume>18</volume>
          <fpage>1249</fpage>
          <lpage>1257</lpage>
          <pub-id pub-id-type="doi">10.1038/modpathol.3800413</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Roesch A, Becker B, Meyer S, Wild P, Hafner C, Landthaler M, Vogt T (2005) Retinoblastoma-binding protein 2-homolog 1: a retinoblastoma-binding protein downregulated in malignant melanomas. Mod Pathol 18:1249&#x2013;1257 <pub-id pub-id-type="pmid">15803180</pub-id></citation>
      </ref>
      <ref id="CR66">
        <label>66.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Saalbach</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Wetzel</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Haustein</surname>
              <given-names>UF</given-names>
            </name>
            <name>
              <surname>Sticherling</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Simon</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Anderegg</surname>
              <given-names>U</given-names>
            </name>
          </person-group>
          <article-title>Interaction of human Thy-1 (CD 90) with the integrin alphavbeta3 (CD51/CD61): an important mechanism mediating melanoma cell adhesion to activated endothelium</article-title>
          <source>Oncogene</source>
          <year>2005</year>
          <volume>24</volume>
          <fpage>4710</fpage>
          <lpage>4720</lpage>
          <pub-id pub-id-type="doi">10.1038/sj.onc.1208559</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Saalbach A, Wetzel A, Haustein UF, Sticherling M, Simon JC, Anderegg U (2005) Interaction of human Thy-1 (CD 90) with the integrin alphavbeta3 (CD51/CD61): an important mechanism mediating melanoma cell adhesion to activated endothelium. Oncogene 24:4710&#x2013;4720 <pub-id pub-id-type="pmid">15897908</pub-id></citation>
      </ref>
      <ref id="CR67">
        <label>67.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Scala</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ottaiano</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ascierto</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Cavalli</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Simeone</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Giuliano</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Napolitano</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Franco</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Botti</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Castello</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma</article-title>
          <source>Clin Cancer Res</source>
          <year>2005</year>
          <volume>11</volume>
          <fpage>1835</fpage>
          <lpage>1841</lpage>
          <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-04-1887</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Scala S, Ottaiano A, Ascierto PA, Cavalli M, Simeone E, Giuliano P, Napolitano M, Franco R, Botti G, Castello G (2005) Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin Cancer Res 11:1835&#x2013;1841 <pub-id pub-id-type="pmid">15756007</pub-id></citation>
      </ref>
      <ref id="CR68">
        <label>68.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Scheibenbogen</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Mohler</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Haefele</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Hunstein</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Keilholz</surname>
              <given-names>U</given-names>
            </name>
          </person-group>
          <article-title>Serum interleukin-8 (IL-8) is elevated in patients with metastatic melanoma and correlates with tumor load</article-title>
          <source>Melanoma Res</source>
          <year>1995</year>
          <volume>5</volume>
          <fpage>179</fpage>
          <lpage>181</lpage>
        </citation>
        <citation citation-type="display-unstructured">Scheibenbogen C, Mohler T, Haefele J, Hunstein W, Keilholz U (1995) Serum interleukin-8 (IL-8) is elevated in patients with metastatic melanoma and correlates with tumor load. Melanoma Res 5:179&#x2013;181 <pub-id pub-id-type="pmid">7640519</pub-id></citation>
      </ref>
      <ref id="CR69">
        <label>69.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schmidt</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Johansen</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Gehl</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Geertsen</surname>
              <given-names>PF</given-names>
            </name>
            <name>
              <surname>Fode</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Maase</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma</article-title>
          <source>Cancer</source>
          <year>2006a</year>
          <volume>106</volume>
          <fpage>1130</fpage>
          <lpage>1139</lpage>
          <pub-id pub-id-type="doi">10.1002/cncr.21678</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Schmidt H, Johansen JS, Gehl J, Geertsen PF, Fode K, von der Maase H (2006a) Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma. Cancer 106:1130&#x2013;1139 <pub-id pub-id-type="pmid">16456816</pub-id></citation>
      </ref>
      <ref id="CR70">
        <label>70.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schmidt</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Johansen</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Sjoegren</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Christensen</surname>
              <given-names>IJ</given-names>
            </name>
            <name>
              <surname>Sorensen</surname>
              <given-names>BS</given-names>
            </name>
            <name>
              <surname>Fode</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Larsen</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Maase</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma</article-title>
          <source>J Clin Oncol</source>
          <year>2006b</year>
          <volume>24</volume>
          <fpage>798</fpage>
          <lpage>804</lpage>
          <pub-id pub-id-type="doi">10.1200/JCO.2005.03.7960</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Schmidt H, Johansen JS, Sjoegren P, Christensen IJ, Sorensen BS, Fode K, Larsen J, von der Maase H (2006b) Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma. J Clin Oncol 24:798&#x2013;804 <pub-id pub-id-type="pmid">16391295</pub-id></citation>
      </ref>
      <ref id="CR71">
        <label>71.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schultz</surname>
              <given-names>ES</given-names>
            </name>
            <name>
              <surname>Diepgen</surname>
              <given-names>TL</given-names>
            </name>
            <name>
              <surname>Driesch</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Clinical and prognostic relevance of serum S-100 beta protein in malignant melanoma</article-title>
          <source>Br J Dermatol</source>
          <year>1998</year>
          <volume>138</volume>
          <fpage>426</fpage>
          <lpage>430</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1365-2133.1998.02119.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Schultz ES, Diepgen TL, Von Den Driesch P (1998) Clinical and prognostic relevance of serum S-100 beta protein in malignant melanoma. Br J Dermatol 138:426&#x2013;430 <pub-id pub-id-type="pmid">9580794</pub-id></citation>
      </ref>
      <ref id="CR72">
        <label>72.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sirott</surname>
              <given-names>MN</given-names>
            </name>
            <name>
              <surname>Bajorin</surname>
              <given-names>DF</given-names>
            </name>
            <name>
              <surname>Wong</surname>
              <given-names>GY</given-names>
            </name>
            <name>
              <surname>Tao</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Chapman</surname>
              <given-names>PB</given-names>
            </name>
            <name>
              <surname>Templeton</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Houghton</surname>
              <given-names>AN</given-names>
            </name>
          </person-group>
          <article-title>Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis</article-title>
          <source>Cancer</source>
          <year>1993</year>
          <volume>72</volume>
          <fpage>3091</fpage>
          <lpage>3098</lpage>
          <pub-id pub-id-type="doi">10.1002/1097-0142(19931115)72:10&lt;3091::AID-CNCR2820721034&gt;3.0.CO;2-V</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Sirott MN, Bajorin DF, Wong GY, Tao Y, Chapman PB, Templeton MA, Houghton AN (1993) Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis. Cancer 72:3091&#x2013;3098 <pub-id pub-id-type="pmid">8221576</pub-id></citation>
      </ref>
      <ref id="CR73">
        <label>73.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Soubrane</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Rixe</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Meric</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Khayat</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Mouawad</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Pretreatment serum interleukin-6 concentration as a prognostic factor of overall survival in metastatic malignant melanoma patients treated with biochemotherapy: a retrospective study</article-title>
          <source>Melanoma Res</source>
          <year>2005</year>
          <volume>15</volume>
          <fpage>199</fpage>
          <lpage>204</lpage>
          <pub-id pub-id-type="doi">10.1097/00008390-200506000-00009</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Soubrane C, Rixe O, Meric JB, Khayat D, Mouawad R (2005) Pretreatment serum interleukin-6 concentration as a prognostic factor of overall survival in metastatic malignant melanoma patients treated with biochemotherapy: a retrospective study. Melanoma Res 15:199&#x2013;204 <pub-id pub-id-type="pmid">15917702</pub-id></citation>
      </ref>
      <ref id="CR74">
        <label>74.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stahlecker</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Gauger</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Bosserhoff</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Buettner</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Ring</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Hein</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>MIA as a reliable tumor marker in the serum of patients with malignant melanoma</article-title>
          <source>Anticancer Res</source>
          <year>2000</year>
          <volume>20</volume>
          <fpage>5041</fpage>
          <lpage>5044</lpage>
        </citation>
        <citation citation-type="display-unstructured">Stahlecker J, Gauger A, Bosserhoff A, Buettner R, Ring J, Hein R (2000) MIA as a reliable tumor marker in the serum of patients with malignant melanoma. Anticancer Res 20:5041&#x2013;5044 <pub-id pub-id-type="pmid">11326664</pub-id></citation>
      </ref>
      <ref id="CR75">
        <label>75.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stoitchkov</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Letellier</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Garnier</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Bousquet</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Tsankov</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Morel</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Ghanem</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Le Bricon</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Evaluation of the serum L-dopa/L-tyrosine ratio as a melanoma marker</article-title>
          <source>Melanoma Res</source>
          <year>2003</year>
          <volume>13</volume>
          <fpage>587</fpage>
          <lpage>593</lpage>
          <pub-id pub-id-type="doi">10.1097/00008390-200312000-00008</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Stoitchkov K, Letellier S, Garnier JP, Bousquet B, Tsankov N, Morel P, Ghanem G, Le Bricon T (2003) Evaluation of the serum L-dopa/L-tyrosine ratio as a melanoma marker. Melanoma Res 13:587&#x2013;593 <pub-id pub-id-type="pmid">14646622</pub-id></citation>
      </ref>
      <ref id="CR76">
        <label>76.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Suiqing</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Min</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Lirong</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Overexpression of phosphorylated-STAT3 correlated with the invasion and metastasis of cutaneous squamous cell carcinoma</article-title>
          <source>J Dermatol</source>
          <year>2005</year>
          <volume>32</volume>
          <fpage>354</fpage>
          <lpage>360</lpage>
        </citation>
        <citation citation-type="display-unstructured">Suiqing C, Min Z, Lirong C (2005) Overexpression of phosphorylated-STAT3 correlated with the invasion and metastasis of cutaneous squamous cell carcinoma. J Dermatol 32:354&#x2013;360 <pub-id pub-id-type="pmid">16043897</pub-id></citation>
      </ref>
      <ref id="CR77">
        <label>77.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Swart</surname>
              <given-names>GW</given-names>
            </name>
            <name>
              <surname>Lunter</surname>
              <given-names>PC</given-names>
            </name>
            <name>
              <surname>Kilsdonk</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Kempen</surname>
              <given-names>LC</given-names>
            </name>
          </person-group>
          <article-title>Activated leukocyte cell adhesion molecule (ALCAM/CD166): signaling at the divide of melanoma cell clustering and cell migration?</article-title>
          <source>Cancer Metastasis Rev</source>
          <year>2005</year>
          <volume>24</volume>
          <fpage>223</fpage>
          <lpage>236</lpage>
          <pub-id pub-id-type="doi">10.1007/s10555-005-1573-0</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Swart GW, Lunter PC, Kilsdonk JW, Kempen LC (2005) Activated leukocyte cell adhesion molecule (ALCAM/CD166): signaling at the divide of melanoma cell clustering and cell migration? Cancer Metastasis Rev 24:223&#x2013;236 <pub-id pub-id-type="pmid">15986133</pub-id></citation>
      </ref>
      <ref id="CR78">
        <label>78.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tas</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Duranyildiz</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Argon</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Oguz</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Camlica</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Yasasever</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Topuz</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Serum bcl-2 and survivin levels in melanoma</article-title>
          <source>Melanoma Res</source>
          <year>2004</year>
          <volume>14</volume>
          <fpage>543</fpage>
          <lpage>546</lpage>
          <pub-id pub-id-type="doi">10.1097/00008390-200412000-00017</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Tas F, Duranyildiz D, Argon A, Oguz H, Camlica H, Yasasever V, Topuz E (2004) Serum bcl-2 and survivin levels in melanoma. Melanoma Res 14:543&#x2013;546 <pub-id pub-id-type="pmid">15577328</pub-id></citation>
      </ref>
      <ref id="CR79">
        <label>79.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thies</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Moll</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Berger</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Wagener</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Brummer</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Schulze</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>Brunner</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Schumacher</surname>
              <given-names>U</given-names>
            </name>
          </person-group>
          <article-title>CEACAM1 expression in cutaneous malignant melanoma predicts the development of metastatic disease</article-title>
          <source>J Clin Oncol</source>
          <year>2002</year>
          <volume>20</volume>
          <fpage>2530</fpage>
          <lpage>2536</lpage>
          <pub-id pub-id-type="doi">10.1200/JCO.2002.05.033</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Thies A, Moll I, Berger J, Wagener C, Brummer J, Schulze HJ, Brunner G, Schumacher U (2002) CEACAM1 expression in cutaneous malignant melanoma predicts the development of metastatic disease. J Clin Oncol 20:2530&#x2013;2536 <pub-id pub-id-type="pmid">12011132</pub-id></citation>
      </ref>
      <ref id="CR80">
        <label>80.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Udart</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Utikal</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Krahn</surname>
              <given-names>GM</given-names>
            </name>
            <name>
              <surname>Peter</surname>
              <given-names>RU</given-names>
            </name>
          </person-group>
          <article-title>Chromosome 7 aneusomy. A marker for metastatic melanoma? Expression of the epidermal growth factor receptor gene and chromosome 7 aneusomy in nevi, primary malignant melanomas and metastases</article-title>
          <source>Neoplasia</source>
          <year>2001</year>
          <volume>3</volume>
          <fpage>245</fpage>
          <lpage>254</lpage>
          <pub-id pub-id-type="doi">10.1038/sj.neo.7900156</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Udart M, Utikal J, Krahn GM, Peter RU (2001) Chromosome 7 aneusomy. A marker for metastatic melanoma? Expression of the epidermal growth factor receptor gene and chromosome 7 aneusomy in nevi, primary malignant melanomas and metastases. Neoplasia 3:245&#x2013;254 <pub-id pub-id-type="pmid">11494118</pub-id></citation>
      </ref>
      <ref id="CR81">
        <label>81.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ugurel</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Bell</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Sucker</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Zimpfer</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Rittgen</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Schadendorf</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Tumor type M2 pyruvate kinase (TuM2-PK) as a novel plasma tumor marker in melanoma</article-title>
          <source>Int J Cancer</source>
          <year>2005a</year>
          <volume>117</volume>
          <fpage>825</fpage>
          <lpage>830</lpage>
          <pub-id pub-id-type="doi">10.1002/ijc.21073</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Ugurel S, Bell N, Sucker A, Zimpfer A, Rittgen W, Schadendorf D (2005a) Tumor type M2 pyruvate kinase (TuM2-PK) as a novel plasma tumor marker in melanoma. Int J Cancer 117:825&#x2013;830 <pub-id pub-id-type="pmid">15957165</pub-id></citation>
      </ref>
      <ref id="CR82">
        <label>82.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ugurel</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hildenbrand</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Zimpfer</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>La Rosee</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Paschka</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Sucker</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Keikavoussi</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Becker</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Rittgen</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Hochhaus</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Lack of clinical efficacy of imatinib in metastatic melanoma</article-title>
          <source>Br J Cancer</source>
          <year>2005b</year>
          <volume>92</volume>
          <fpage>1398</fpage>
          <lpage>1405</lpage>
          <pub-id pub-id-type="doi">10.1038/sj.bjc.6602529</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Ugurel S, Hildenbrand R, Zimpfer A, La Rosee P, Paschka P, Sucker A, Keikavoussi P, Becker JC, Rittgen W, Hochhaus A, et al (2005b) Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer 92:1398&#x2013;1405 <pub-id pub-id-type="pmid">15846297</pub-id></citation>
      </ref>
      <ref id="CR83">
        <label>83.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ugurel</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Rappl</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Tilgen</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Reinhold</surname>
              <given-names>U</given-names>
            </name>
          </person-group>
          <article-title>Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival</article-title>
          <source>J Clin Oncol</source>
          <year>2001a</year>
          <volume>19</volume>
          <fpage>577</fpage>
          <lpage>583</lpage>
        </citation>
        <citation citation-type="display-unstructured">Ugurel S, Rappl G, Tilgen W, Reinhold U (2001a) Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol 19:577&#x2013;583 <pub-id pub-id-type="pmid">11208853</pub-id></citation>
      </ref>
      <ref id="CR84">
        <label>84.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ugurel</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Rappl</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Tilgen</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Reinhold</surname>
              <given-names>U</given-names>
            </name>
          </person-group>
          <article-title>Increased soluble CD95 (sFas/CD95) serum level correlates with poor prognosis in melanoma patients</article-title>
          <source>Clin Cancer Res</source>
          <year>2001b</year>
          <volume>7</volume>
          <fpage>1282</fpage>
          <lpage>1286</lpage>
        </citation>
        <citation citation-type="display-unstructured">Ugurel S, Rappl G, Tilgen W, Reinhold U (2001b) Increased soluble CD95 (sFas/CD95) serum level correlates with poor prognosis in melanoma patients. Clin Cancer Res 7:1282&#x2013;1286 <pub-id pub-id-type="pmid">11350895</pub-id></citation>
      </ref>
      <ref id="CR85">
        <label>85.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vergilis</surname>
              <given-names>IJ</given-names>
            </name>
            <name>
              <surname>Szarek</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ferrone</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Reynolds</surname>
              <given-names>SR</given-names>
            </name>
          </person-group>
          <article-title>Presence and prognostic significance of melanoma-associated antigens CYT-MAA and HMW-MAA in serum of patients with melanoma</article-title>
          <source>J Invest Dermatol</source>
          <year>2005</year>
          <volume>125</volume>
          <fpage>526</fpage>
          <lpage>531</lpage>
          <pub-id pub-id-type="doi">10.1111/j.0022-202X.2005.23798.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Vergilis IJ, Szarek M, Ferrone S, Reynolds SR (2005) Presence and prognostic significance of melanoma-associated antigens CYT-MAA and HMW-MAA in serum of patients with melanoma. J Invest Dermatol 125:526&#x2013;531 <pub-id pub-id-type="pmid">16117794</pub-id></citation>
      </ref>
      <ref id="CR86">
        <label>86.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vonderheid</surname>
              <given-names>EC</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Lessin</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Polansky</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Abrams</surname>
              <given-names>JT</given-names>
            </name>
            <name>
              <surname>Bigler</surname>
              <given-names>RD</given-names>
            </name>
            <name>
              <surname>Wasik</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
          <article-title>Use of serum soluble interleukin-2 receptor levels to monitor the progression of cutaneous T-cell lymphoma</article-title>
          <source>J Am Acad Dermatol</source>
          <year>1998</year>
          <volume>38</volume>
          <fpage>207</fpage>
          <lpage>220</lpage>
          <pub-id pub-id-type="doi">10.1016/S0190-9622(98)70597-3</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Vonderheid EC, Zhang Q, Lessin SR, Polansky M, Abrams JT, Bigler RD, Wasik MA (1998) Use of serum soluble interleukin-2 receptor levels to monitor the progression of cutaneous T-cell lymphoma. J Am Acad Dermatol 38:207&#x2013;220 <pub-id pub-id-type="pmid">9486676</pub-id></citation>
      </ref>
      <ref id="CR87">
        <label>87.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vuoristo</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Laine</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Huhtala</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Parvinen</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Hahka-Kemppinen</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Korpela</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kumpulainen</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Kellokumpu-Lehtinen</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Serum adhesion molecules and interleukin-2 receptor as markers of tumour load and prognosis in advanced cutaneous melanoma</article-title>
          <source>Eur J Cancer</source>
          <year>2001</year>
          <volume>37</volume>
          <fpage>1629</fpage>
          <lpage>1634</lpage>
          <pub-id pub-id-type="doi">10.1016/S0959-8049(01)00192-7</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Vuoristo MS, Laine S, Huhtala H, Parvinen LM, Hahka-Kemppinen M, Korpela M, Kumpulainen E, Kellokumpu-Lehtinen P (2001) Serum adhesion molecules and interleukin-2 receptor as markers of tumour load and prognosis in advanced cutaneous melanoma. Eur J Cancer 37:1629&#x2013;1634 <pub-id pub-id-type="pmid">11527688</pub-id></citation>
      </ref>
      <ref id="CR88">
        <label>88.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Weinlich</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Eisendle</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Hassler</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Baltaci</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Fritsch</surname>
              <given-names>PO</given-names>
            </name>
            <name>
              <surname>Zelger</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Metallothionein&#x2014;overexpression as a highly significant prognostic factor in melanoma: a prospective study on 1270 patients</article-title>
          <source>Br J Cancer</source>
          <year>2006</year>
          <volume>94</volume>
          <fpage>835</fpage>
          <lpage>841</lpage>
          <pub-id pub-id-type="doi">10.1038/sj.bjc.6603028</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Weinlich G, Eisendle K, Hassler E, Baltaci M, Fritsch PO, Zelger B (2006) Metallothionein&#x2014;overexpression as a highly significant prognostic factor in melanoma: a prospective study on 1270 patients. Br J Cancer 94:835&#x2013;841 <pub-id pub-id-type="pmid">16508630</pub-id></citation>
      </ref>
      <ref id="CR89">
        <label>89.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Westhoff</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Fox</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Otto</surname>
              <given-names>FJ</given-names>
            </name>
          </person-group>
          <article-title>Soluble HLA class I antigens in plasma of patients with malignant melanoma</article-title>
          <source>Anticancer Res</source>
          <year>1998</year>
          <volume>18</volume>
          <fpage>3789</fpage>
          <lpage>3792</lpage>
        </citation>
        <citation citation-type="display-unstructured">Westhoff U, Fox C, Otto FJ (1998) Soluble HLA class I antigens in plasma of patients with malignant melanoma. Anticancer Res 18:3789&#x2013;3792 <pub-id pub-id-type="pmid">9854497</pub-id></citation>
      </ref>
      <ref id="CR90">
        <label>90.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Willemze</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Jaffe</surname>
              <given-names>ES</given-names>
            </name>
            <name>
              <surname>Burg</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Cerroni</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Berti</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Swerdlow</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Ralfkiaer</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Chimenti</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Diaz-Perez</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Duncan</surname>
              <given-names>LM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>WHO-EORTC classification for cutaneous lymphomas</article-title>
          <source>Blood</source>
          <year>2005</year>
          <volume>105</volume>
          <fpage>3768</fpage>
          <lpage>3785</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2004-09-3502</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, Ralfkiaer E, Chimenti S, Diaz-Perez JL, Duncan LM, et al (2005) WHO-EORTC classification for cutaneous lymphomas. Blood 105:3768&#x2013;3785 <pub-id pub-id-type="pmid">15692063</pub-id></citation>
      </ref>
      <ref id="CR91">
        <label>91.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wimmer</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Meyer</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Seifert</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Dummer</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Flace</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Burg</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Prognostic value of serum 5-S-cysteinyldopa for monitoring human metastatic melanoma during immunochemotherapy</article-title>
          <source>Cancer Res</source>
          <year>1997</year>
          <volume>57</volume>
          <fpage>5073</fpage>
          <lpage>5076</lpage>
        </citation>
        <citation citation-type="display-unstructured">Wimmer I, Meyer JC, Seifert B, Dummer R, Flace A, Burg G (1997) Prognostic value of serum 5-S-cysteinyldopa for monitoring human metastatic melanoma during immunochemotherapy. Cancer Res 57:5073&#x2013;5076 <pub-id pub-id-type="pmid">9371505</pub-id></citation>
      </ref>
      <ref id="CR92">
        <label>92.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Winnepenninckx</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Lazar</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Michiels</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Dessen</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Stas</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Alonso</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Avril</surname>
              <given-names>MF</given-names>
            </name>
            <name>
              <surname>Ortiz Romero</surname>
              <given-names>PL</given-names>
            </name>
            <name>
              <surname>Robert</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Balacescu</surname>
              <given-names>O</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Gene expression profiling of primary cutaneous melanoma and clinical outcome</article-title>
          <source>J Natl Cancer Inst</source>
          <year>2006</year>
          <volume>98</volume>
          <fpage>472</fpage>
          <lpage>482</lpage>
        </citation>
        <citation citation-type="display-unstructured">Winnepenninckx V, Lazar V, Michiels S, Dessen P, Stas M, Alonso SR, Avril MF, Ortiz Romero PL, Robert T, Balacescu O, et al (2006) Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst 98:472&#x2013;482 <pub-id pub-id-type="pmid">16595783</pub-id></citation>
      </ref>
      <ref id="CR93">
        <label>93.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wu</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Barusevicius</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Babb</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Klein-Szanto</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Godwin</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Elenitsas</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Gelfand</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Lessin</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Seykora</surname>
              <given-names>JT</given-names>
            </name>
          </person-group>
          <article-title>Pleiotrophin expression correlates with melanocytic tumor progression and metastatic potential</article-title>
          <source>J Cutan Pathol</source>
          <year>2005</year>
          <volume>32</volume>
          <fpage>125</fpage>
          <lpage>130</lpage>
          <pub-id pub-id-type="doi">10.1111/j.0303-6987.2005.00282.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Wu H, Barusevicius A, Babb J, Klein-Szanto A, Godwin A, Elenitsas R, Gelfand JM, Lessin S, Seykora JT (2005) Pleiotrophin expression correlates with melanocytic tumor progression and metastatic potential. J Cutan Pathol 32:125&#x2013;130 <pub-id pub-id-type="pmid">15606670</pub-id></citation>
      </ref>
      <ref id="CR94">
        <label>94.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yamada</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Yanaba</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Takehara</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Sato</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Clinical significance of serum levels of soluble intercellular adhesion molecule-1 and soluble L-selectin in malignant melanoma</article-title>
          <source>Arch Dermatol Res</source>
          <year>2005</year>
          <volume>297</volume>
          <fpage>256</fpage>
          <lpage>260</lpage>
          <pub-id pub-id-type="doi">10.1007/s00403-005-0605-5</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Yamada M, Yanaba K, Takehara K, Sato S (2005) Clinical significance of serum levels of soluble intercellular adhesion molecule-1 and soluble L-selectin in malignant melanoma. Arch Dermatol Res 297:256&#x2013;260 <pub-id pub-id-type="pmid">16222535</pub-id></citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>